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Zusammenfassung 
 
Eine systemische Entzündungsreaktion tritt häufig bei einer progressiven 
Krebserkrankung auf. Die auf den Entzündungsreiz hin aktivierte Immunantwort ist 
außer Kontrolle geraten und führt zur gravierenden Ausschüttung an pro-
inflammatorischen Zytokinen, z.B. TNF-α. Diese dyfunktionale Immunreaktion führt 
zur Beeinträchtigung von bis dato gesunden Organen, wie z.B. dem Skelettmuskel. Die 
dem Prozeß der Muskelatrophie zugrundeliegenden molekularen Mechanismen sind 
insbesondere auf transkriptioneller Ebene weitestgehend unbekannt. 
Aus diesem Grund wurde ein zellbasierter Screen im Hochdurchsatzverfahren 
durchgeführt, um jene transkriptionelle Regulatoren zu identifizieren, deren Aktivität 
sich unter atrophischen Bedingungen verändert. Eine Behandlung von HEK293T Zellen 
mit TNF-α führte zu einer deutlichen Erniedrigung der transkriptionellen Aktivität der 
DNA-bindenden Komponente des Ets Transkriptions Faktors GAbp, GAbpα. Die für 
die transkriptionelle Aktivität notwendige funktionale Interaktion von GAbpα mit der 
zweiten GAbp Untereinheit, GAbpβ, war in TNF-α behandelten C2C12 Zellen, einer 
murinen Muskelzelllinie, ebenfalls signifikant reduziert. Weiterhin konnte gezeigt 
werden, daß die Dissoziation des transkriptionell aktiven Heterodimers lediglich die 
minimalen Bindedomänen von GAbpα und GAbpβ benötigt, für TNF-α spezifisch ist 
und über eine intrazellulären Anhäufung von reaktiven Sauerstoff-Spezies (ROS) 
erfolgt. Im Muskel wird die Aktivität von GAbp durch den Wachstumsfaktor 
Neuregulin (NRG) erhöht und führt zur Expression von sub-synaptischen Genen (z.B. 
epsilon Untereinheit des Acetylcholin-Rezeptors (AChRε)), welche für die Innervation 
des Muskels durch motorische Nervenzellen unerläßlich sind. Die NRG-abhängige 
Aktivierung des AChRε-Promotors als auch der AChRε-mRNA Expression wurde in 
Gegenwart von TNF-α signifikant eingeschränkt, wobei diese Effekte spezifisch für 
TNF-α waren und über ROS erfolgten. Zudem war die Expression von sub-synaptischen 
GAbp Zielgenen in einem Mausmodel entzündlicher Tumorkachexie inhibiert. 
Eine pro-inflammatorische Stimulation von Muskelzellen führt über intrazellulär 
aktivierte ROS zur Erniedrigung der transkriptionellen Aktivität von GAbp. Die daraus 
resultierende reduzierte Genexpression von sub-synaptischen GAbp Zielgenen könnte 
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zur Denervation des Muskels führen und somit wesentlich zur Muskelatrophie im 
Kontext systemischer Entzündungsreaktionen oder des Alterungsprozesses beitragen. 
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Summary 
 
Cancer and the Metabolic Syndrome are debilitating human diseases being 
accompanied by a dysregulated immune response frequently resulting in systemic 
inflammatory processes. Circulating pro-inflammatory cytokines (e.g. TNF-α) target 
metabolic tissues, like skeletal muscle - a process leading to muscle atrophy. The 
molecular mechanisms of the underlying transcriptional control still remain elusive. 
Therefore, the identification of transcriptional regulators with altered transcriptional 
activity in response to atrophic conditions was addressed in this study.  
In a cell-based high-throughput screen, the transcriptional activity of GAbpα, the 
DNA-binding component of the Ets transcription factor GAbp, significantly decreased 
upon TNF-α treatment. Subsequent analysis in the murine muscle cell line C2C12 
revealed that reactive oxygen species (ROS) mediate TNF-α-dependet dissociation of 
GAbpα and GAbpβ, the transcriptional activation domain component of GAbp. This 
alteration of GAbp complex interaction was specific to TNF-α, and the minimal binding 
domains of GAbpα and GAbpβ were sufficient for TNF-α mediated dissociation. 
Moreover, TNF-α efficiently blocked the neuregulin growth factor (NRG) mediated 
activation of a GAbpα the DNA consensus motif of GAbpα, thus suggesting that 
dissociation of the transcriptional active GAbp heterodimer is implicated in GAbp target 
gene expression. This was further supported by the finding that NRG-induced 
expression of the sub-synaptic GAbp target gene, epsilon subunit of the acetylcholine 
receptor (AChRε), was restraint specifically by TNF-α. ROS inhibitors efficiently 
rescued this altered gene expression of AChRε under pro-inflammatory conditions. 
Taken together, formation of ROS links pro-inflammatory TNF-α signalling in 
muscle cells to GAbp complex dissociation and thereby decreases the transcriptional 
activity of GAbp. This altered activity leads to decreased gene expression of GAbp sub-
synaptic target genes; thus, suggesting that accumulation of ROS under atrophic 
conditions may lead to denervation of muscle cells causing muscle atrophy. 
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LeuZip Basic Leucine zipper domain 
LPS Lipopolysaccharides 
Luc Luciferase Reporter 
miRNA Micro RNA 
MAFbx/ atrogin-1 Muscle Atrophy F-box 
MCS Multiple cloning site 
miRNA Micro RNA 
MnTBAP Mn(III)tetrakis(4-benzoic acid)porphyrin 
Chloride 
MOI Multiplicity of infection 
MRF Myogenic regulatory factor 
MuRF1 Muscle RING Finger 1 
MuSk Muscle-specific tyrosine protein kinase receptor 
NAC N-acetycysteine 
NC Negative control 
NF-κB Nuclear factor κB 
NLS Nuclear localization signal 
NMJ Neuromuscular junction 
NRG Neuregulin (here: human NRG-β1/HRG- β1) 
ORF Open reading frame 
ON overnight 
PCI Phenol:Chloroform:Isoamylalkohol 
PCR Polymerase chain reaction 
PhoSit Phosphorylation sites 
PNT Pointed domain 
PPI Protein-Protein Interaction 
P/S Penicillin-Streptomycin 
PSPC1 Paraspeckle component 1 
qRT-PCR Quantitative Real-Time PCR 
RNA Ribonucleic acid 
ROS Reactive oxygen species 
RT Room temperature 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel 
electrophoresis 
TAD Transcriptional activation domain 
TBP TATA binding protein 
TF Transcription factor 
TNF-α Tumour necrosis factor-alpha 
TU Transforming units 
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Vp16 TAD from herpes simplex virus (HSV) 
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1 Introduction 
 
1.1 Inflammation – an Adaptive Response to Severe 
Disturbances of Body Homeostasis 
Inflammatory pathways of the innate and adaptive immune response are activated in 
response to infection or tissue injury and represent a disturbance of body homeostasis. 
The ultimate goal of the innate and adaptive immune response is to combat infection, to 
restore tissue structure and function, and regain thereby a vital body homeostasis. Much 
progress has been made in understanding the acute inflammatory reactions, being 
activated upon infection or tissue injury, and the localized chronic inflammation 
pathways, being triggered upon autoimmune diseases and chronic infections 
(Medzhitov 2008). However, the events leading to subacute or chronic inflammation 
still await their detailed understanding. In these cases, the immune response is incapable 
to clearly resolve the inflammation process at the site of origin. Moreover, a persistent 
inflammation response may even emanate to other tissues by circulating inflammatory 
mediators, a progress named systemic inflammation. Cancer and the Metabolic 
Syndrome (including obesity, insulin resistance, atherosclerosis, etc.) are often 
accompanied by a systemic inflammation response. Since the abundance of food and 
increased life expectancy are no more solely characteristics of the western industrialized 
nations, the prevalence for developing cancer and/ or the Metabolic Syndrome increases 
worldwide (Popkin 2007). In this context, several epidemiological studies indicate that 
several types of cancer are obesity related suggesting a correlation between these two 
diseases (Calle & Kaaks 2004). 
The inflammatory pathway is characterized by coordinated reactions of the innate and 
adaptive immune response. The innate immune system, being activated within minutes 
to hours, consists of phagocytes, antigen-presenting cells, the complement system and 
natural killer cells. It functions to recognize, label and neutralize - by binding or 
destruction - the noxious stimulus. Most importantly, the innate immune response 
informs the adaptive immune response, so that the latter can mount an adequate 
reaction. A “classical” inflammatory reaction can be functionally categorized into four 
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participating classes: inducers, sensors, mediators, effectors (Medzhitov 2008) (Figure 
1). The release of cellular constituents, ATP and K+ ions for instance, from a necrotic 
cell represents an endogenous inducer. These components may be detected by tissue-
resident macrophages (sensors), which in turn produce cytokines (mediators). 
Macrophages are able to distinguish whether the surrounding tissue cells are in a basal 
or malfunctioning state and report accordingly to the immune system. Finally, the 
released cytokines act on tissues and organs (effectors) leading to diverse reactions as 
further recruitment and activation of the components of the innate immune response and 
the development of a highly specific memory by the adaptive immune response. A 
chronic inflammation response is characterized by abnormal cytokine production, 
increased acute-phase reactants, activation of a cascade of inflammatory signalling 
pathways and the dominating presence of macrophages in the injured tissue 
(Hotamisligil 2006). These activated macrophages release inflammatory mediators 
which may act on otherwise healthy tissue turning the inflammation response into a 
systemic inflammation process. 
Inducers  →  Sensors  →  Mediators  →  Effectors
e.g.
LPS
e.g.
Macro-
phages
e.g.
TNF-α
e.g.
Muscle Cells
 
Figure 1: Inducers, sensors, mediators and effectors are involved in the course of a generic 
inflammatory pathway. LPS, an exogenous inducer, causes activation of macrophages, which act hereby 
as sensors. This process triggers the secretion of TNF-α from macrophages and finally effects tissues as 
the muscle. However, inducers such as LPS can also act directly on effectors (Medzhitov 2008). 
On the molecular level, two signalling pathways have emerged as important regulators 
of the coordinated immune response with yet opposing reactions (Figure 2). While the 
pro-inflammatory nuclear factor (NF)-κB pathway promotes expression of cytokines 
and acute phase proteins, the glucocorticoid-mediated signalling pathway causes an 
inhibition of pro-inflammatory cytokine expression (McKay & Cidlowski 1999). The 
NF-κB signalling cascade is activated via extracellular stimuli, such as pro-
inflammatory cytokines (e.g. tumor necrosis factor (TNF)-α), lipopolysaccharide (LPS) 
or oxidative stressors. NF-κB is a dimeric transcription factor with the p65/p50 
heterodimer representing the “classical” NF-κB heterodimer. Under unstimulated 
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conditions NF-κB resides in the cytoplasm while bound to the NF-κB inhibitory protein 
(IκBα). Upon activation of the pathway, IκBα is phosphorylated and targeted to protein 
degradation via ubiquitylation. Thereby, the nuclear localization signal (NLS) on the 
p65 subunit gets exposed, and the dimer shuttles into the nucleus where it binds to κB-
responsive elements in promoter sequences of target genes (Figure 2). 
 
Figure 2: The NF-κB and glucocorticoid receptor (GR) pathway act as physiological antagonists 
during an inflammation response. While the NF-κB pathway drives production of pro-inflammatory 
cytokines, the GR pathway suppresses this effect. See text for details (McKay & Cidlowski 1999). 
The anti-inflammatory response via glucocorticoid signalling is driven by binding of 
glucocorticoids to their cognate receptor, the glucocorticoid receptor (GR). GR is also 
anchored in the cytoplasm in complex with inhibitor proteins (Hsp90). The canonical 
GR pathway is then activated by binding of the hormone ligand to its cognate receptor 
with subsequent translocation into the nucleus, homodimerization of the GR and 
binding to glucocorticoid response elements (GRE) in promoter sequences of respective 
target genes (Figure 2). Glucocorticoids are a class of steroid hormones which are 
involved in glucose metabolism. In this context, they stimulate hepatic gluconeogenesis 
by transcriptional activation of genes crucial for gluconeogenesis. Furthermore, they 
mediate the mobilization of amino acids from extrahepatic tissues, inhibit glucose 
uptake in muscle and adipose tissue, and stimulate lipolysis in adipose tissue. Due to 
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their potent anti-inflammatory properties, glucocorticoids are widely used as immune 
suppressive drugs. However, when used for a longer time period or at higher doses, the 
desired anti-inflammatory effects of glucocorticoids are opposed by its role in 
regulating glucose metabolism. In this setting, the degradation of amino acids from 
muscle tissue for hepatic gluconeogenesis can cause serious tissue damage to the 
muscle (Goldberg 1969). 
A balanced action of both pro- and anti-inflammatory pathways is a prerequisite for a 
controlled inflammation response. Usually, this response continues until the affected 
tissue-site is restored in its functionality. However, a dysregulated or chronic 
inflammation response can become detrimental resulting in serious tissue damage of 
otherwise healthy tissues, which did not contain the primary site of origin for the 
inflammation process. The skeletal muscle is one putative secondary effector site in the 
context of a systemic subacute or chronic inflammation. 
Moreover, skeletal muscle atrophy and insulin resistance of the muscle have been 
reported to be associated with certain types of cancer and the Metabolic Syndrome 
(Tisdale 2002; Wei et al. 2008). However, the detailed understanding of these 
pathological states of muscle tissue is still unresolved. 
1.2 Muscle Atrophy – a Dysregulation of Muscle Mass 
Homeostasis Occurring under Chronic Inflammation 
The main function of the skeletal muscle is contraction, which is accomplished on the 
molecular level by the interaction between two muscle specific proteins, myosin and 
actin. In addition to this actomyosin complex, the neuromuscular junction (NMJ) 
represents another structural prerequisite for muscle contraction. The neuromuscular 
junction includes the nerve terminal of a motor neuron and the sub-synaptic membrane 
of an innervated skeletal muscle cell, both cells being separated from another through 
the synaptic cleft (Mejat et al. 2003). Secretion of the neurotransmitter acetylcholine 
from the nerve cell and binding to the nicotinic acetylcholine receptor (AChR), a 
heteropentameric (AChRα2βγ/εδ) ligand-gated ion-channel, at the muscle cell induces a 
structural conformation change, which results finally in muscle contraction. During 
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early neonatal development, the fetal γ-subunit of the AChR is replaced by the ε-
subunit. The latter has been shown to be crucial for the NMJ, since in vivo deletion lead 
to muscle weakness and atrophy (Witzemann et al. 1996). Besides the function to 
innervate the muscle, the motor neuron exerts also a trophic influence on the skeletal 
muscle by secreting growth factors, as for instance neuregulins, which induce muscle 
specific transcription of sub-synaptic target genes.  
The healthy state of muscle metabolism is tightly regulated by anabolic and catabolic 
processes. A dysregulation of this homeostasis results in either increase or decrease of 
muscle mass, named accordingly hypertrophy or atrophy. Skeletal muscle atrophy is 
most often characterized by a reduced protein synthesis and augmented proteolysis. 
Fasting, tissue injury, denervation or disuse are known triggers for skeletal muscle 
atrophy. In addition, muscle atrophy has been also observed in the context of systemic 
diseases, such as insulin resistance and certain types of cancer. Upon association with 
chronic diseases this pathology is called cachexia (McKinnell & Rudnicki 2004). Since 
augmented proteolysis is a hallmark of skeletal muscle atrophy, focus has been put on 
elucidating this catabolic pathway in skeletal muscle tissue. The degradation of proteins 
in muscle cells is accomplished by lysosomal proteolysis, calpains or the ATP 
ubiquitin-dependent proteasome. While extracellular proteins are degraded by the 
lysosomal system, intracellular proteins are substrates to the calpains and the 
proteasome (Tisdale 2002). Of these three pathways, the ATP ubiquitin-dependent 
proteolytic pathway was shown to be predominant in muscle atrophy. Proteins destined 
for degradation are recognized by ubiquitin ligases and accordingly covalently 
conjugated to multiple chains of the 76-amino acid polypeptide ubiquitin. Such 
posttranslationally modified proteins are terminally targeted to the proteasome for 
proteolysis.  
In the past decade, two ubiquitin protein ligases have been discovered to play a crucial 
role in different states of muscle atrophy: Muscle RING Finger 1 (MuRF1) and Muscle 
Atrophy Factor F-box (MAFbx). Bodine et al. identified both ubiquitin protein ligases 
to be upregulated in three in vivo models of skeletal muscle atrophy, denervation, 
immobilization and hindlimb suspension (Bodine et al. 2001). In another study, the 
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mRNA levels of MAFbx were found to be augmented in a fasting model of atrophy and 
hence this protein was also named atrogin-1 (Gomes et al. 2001). Moreover, the 
expression of MuRF1 and MAFbx was increased in two further in vivo models of 
muscle atrophy: systemic treatment with either the pro-inflammatory cytokine 
interleukin-1 (IL-1) or the synthetic glucocorticoid dexamethasone (Dex) (Bodine et al. 
2001). Additionally, activation of the inflammatory nuclear factor (NF)-κB pathway 
was found to enhance MuRF1 promoter activity in C2C12 cells, a murine muscle cell 
line (Cai et al. 2004). These diverse in vivo and in vitro models, suggest that the up-
regulation of ubiquitin ligases, which are implicated in proteolysis via the ATP-
dependent proteasome pathway, represents a common feature of muscle atrophy. 
Furthermore, the increased catabolism in muscle tissue undergoing atrophy seems to be 
mediated by both NF-κB- and glucocorticoid-signalling. 
1.3 Molecular Mechanisms Leading to Muscle Hypertrophy 
and Atrophy 
Following the initial discovery of the two ubiquitin protein ligases being implicated in 
skeletal muscle atrophy, the detailed understanding of the molecular events was of 
significant interest. More precisely, the question to answer was, if anabolic pathways 
were likewise dysregulated as catabolic pathways. Insulin and insulin-like growth factor 
I (IGF-1) are known to counteract the effects of glucocorticoids by promoting protein 
synthesis and growth (Ma et al. 2003). IGF-1 mediated activation of Akt by 
phosphorylation results in augmented protein synthesis promoted mainly by Akt targets 
such as Glycogen synthase kinase 3 (GSK3) or the mammalian target of rapamycin 
(mTOR). In addition, IGF-1 was shown to reduce atrogin-1 expression via the IGF-
1/PI3K/Akt pathway (Sacheck et al. 2004; Stitt et al. 2004). In this context, Sandri et al. 
have shown that upon inhibition of Foxo3, this transcription factor is unable to induce 
expression of MAFbx/atrogin-1 mRNA (Sandri et al. 2004). In parallel, Akt 
phosphorylates FOXO transcription factors thereby excluding them from entry into the 
nucleus and rendering them transcriptionally inactive (Stitt et al. 2004). Thus, the up-
regulation of the ubiquitin ligase MAFbx/atrogin-1 is inhibited under anabolic 
conditions providing a molecular mechanism for decreased catabolism in muscle 
hypertrophy.  
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Figure 3: The PI3K/Akt signal transduction pathway in muscle hypertrophy and atrophy 
(McKinnell & Rudnicki 2004). Binding of the insulin growth factor (IGF-1) to its cognate receptor on 
the cell membrane activates the PI3Kinase pathway resulting finally in phosphorylation of the Foxo 
transcription factor. Such modified Foxo remains in the cytoplasm and is prevented from inducing 
expression of MAFbx/atrogin-1 mRNA within the nucleus. This molecular mechanism causes most 
probably muscle hypertrophy. In contrast, muscle atrophy is triggered by factors such as TNF-α, and the 
NF-κB pathway. In this context, expression of the ubiquitin ligases is increased and leads to protein 
breakdown.  In conditions of disuse or cachexia, this pathway is dysregulated and an inactive Akt protein 
unable to phosphorylate Foxo allowing Foxo to enter the nucleus and driving expression of the ubiquitin 
ligase atrogin-1. (Illustration by courtesy of U.Hardeland, DKFZ, Heidelberg) 
Along with the discovery that a dysregulated PI3K/Akt pathway contributes to skeletal 
muscle atrophy in vitro and in vivo, the involvement of the NF-κB pathway in muscle 
atrophy was addressed in detail (McKinnell & Rudnicki 2004). Similarly to the 
implication of Foxo proteins in ubiquitin-dependent proteolysis, the transcription factor 
NF-κB was shown to induce the expression of the ubiquitin protein ligase MuRF1 (Cai 
et al. 2004). However, the expression of MAFbx/atrogin-1 was not altered in this mouse 
model of muscle atrophy. Thus, while both ubiquitin ligases are targets of Dex mediated 
muscle atrophy, the NF-κB pathway targets specifically MuRF1. 
While IGF-1 stimulates the PI3K/Akt pathway, the NF-κB pathway is activated by 
TNF-α or other pro-inflammatory cytokines. Chronic exposure of mice to TNF-α 
resulted in a dramatic reduction of body weight (Oliff et al. 1987). TNF-α was also 
shown to cause atrophy in vitro: TNF-α stimulation of differentiated C2C12 myocytes 
stimulated loss of myosin heavy chain most probably by activation of the NF-κB 
pathway (Li et al. 1998). Along with this, TNF-α has been implicated in obese humans 
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undergoing a chronic inflammation (Hotamisligil 2006). A similar observation, 
impaired insulin signalling, was also made in TNF-α treated C2C12 myotubes (del 
Aguila et al. 1999). To conclude, while IGF-1 promotes muscle hypertrophy, TNF-α 
induces muscle atrophy. In the course of an inflammation response, TNF-α is secreted 
from macrophages upon activation with LPS, and functions by activating neutrophils 
and mobilizing energy stores (Renz et al. 1992) (Figure 1). However, once released in 
larger quantities during a chronic or systemic inflammation, the otherwise beneficial 
effects turn to a debilitating threat for body homeostasis. Since this protein was found to 
play a role in cachexia, TNF-α was originally named cachectin, (Beutler & Cerami 
1986). 
As targets for the ubiquitin protein ligases several muscle specific proteins were found 
in C2C12 cells. Among those, MyoD was shown to be ubiquitinated by 
MAFbx/atrogin-1, while MuRF1 was responsible for degradation of the myosin heavy 
chain protein (Clarke et al. 2007; Tintignac et al. 2005). Myosin is a component of the 
actomyosin complex which allows muscle fibers to contract. Hence, its degradation 
results in the destruction of the actomyosin complex and loss of muscle movement. 
MyoD is a transcription factor belonging to the family of myogenic regulatory factors 
(MRFs), which is responsible for the differentiation of muscle precursor cells (satellite 
cells) into muscle cells during normal growth or regeneration of muscle tissue. The 
proteolysis of this transcription factor under atrophic conditions suggests that the 
differentiation of satellite cells is likewise affected. TNF-α was also found to decrease 
mRNA and protein levels of muscle specific proteins, such as MyoD and myosin heavy 
chain, via the activation of the NF-κB pathway in C2C12 cells (Acharyya et al. 2004; 
Guttridge et al. 2000; Langen et al. 2004). 
1.4 Assembly of Multiprotein Complexes on Eukaryotic 
Promoter Sequences drives Gene Transcription 
The molecular events leading to muscle atrophy may in fact involve also other 
intracellular signalling pathways than the two “classical” pathways for NF-κB- and GR-
mediated signalling. In addition to excessive glucocorticoid or TNF-α levels, other pro-
inflammatory cytokines, such as Interleukin (IL)-6, IL-1 and Interferon (IFN)-γ have 
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been shown to be implicated in different models of muscle atrophy (Guttridge et al. 
2000; Strassmann et al. 1994). Binding of these cytokines to their cognate receptors 
drives intracellular signalling cascades, finally resulting in altered expression of several 
target genes in muscle tissue. Ubiquitin ligases, myosin heavy chain, and MyoD are 
examples for such regulated target genes. However, the molecular events, namely on the 
transcriptional level in the nucleus remain elusive with the FoxO family of transcription 
factors representing so far the only exception (Accili & Arden 2004). 
DNA-binding
Protein
binding
Transcriptional regulators
 
Figure 4: Eukaryotic transcriptional complexes assemble on DNA promoter sequences of target 
genes (Adapted for modification from Garland Science 2007). The promoter sequences may 
encompass several kilobases DNA. In addition, DNA transcription control elements which are then bound 
by proteins from the transcriptional complex may also be located many kilobases upstream or 
downstream from the start site of transcription within enhancer sequences. The transcriptionl complexes 
are composed of three levels of proteins: Specialized transcription factors, which can be further 
distinguished into DNA-binding and protein-binding proteins, co-regulators, and basal or general 
transcriptional proteins. Both, DNA-binding proteins and co-regulators can either activate or repress 
transcription of target genes and are hence named also activators or repressors. 
A cell within a multicellular organism continuously receives signals, such as cytokines 
in the context of an inflammatory response. Part of these signals induces short-term 
responses, for instance modification of cellular metabolism. In addition, these signals 
can cause changes of gene expression patterns. These long-term responses are required 
for differentiation or division and are accomplished by formation of multiprotein 
transcriptional complexes on promoter sequences. Transcriptional complexes are 
composed of three different levels of proteins: DNA binding proteins, co-regulators and 
basal transcriptional proteins (Amelio et al. 2007). Basal transcriptional proteins can be 
further sub-categorized into the RNA polymerase, the general transcription factors, 
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chromatin remodelers, histone acetylases, deacetylases, kinases, and methylases. These 
proteins are along with the co-regulators ubiquitously present in all eukaryotic cells and 
crucial for the initiation of every RNA polymerase II primary transcript. However, 
regulation of gene transcription depends on DNA binding proteins. DNA binding 
proteins contain a DNA binding domain enabling them to bind characteristic nucleotide 
sequences on the DNA (e.g. GRE). In addition, these proteins contain one or two (e.g. 
GR) activation domains which interact with other proteins thereby stimulating 
transcription of the corresponding target gene. In contrast, co-regulators interact via 
protein-protein-interaction domains (e.g. ankyrin repeats) with DNA binding proteins 
and proteins of the basal transcriptional machinery (Figure 4). In this study, both DNA 
binding proteins and co-regulators are referred to as transcriptional regulators. They can 
either activate or repress transcription of genes and are accordingly named activators or 
repressors, respectively. Interestingly, the modular structure of DNA binding proteins 
can be shared between partner proteins with one protein containing the DNA binding 
domain and the other containing the transcription activation domain. The Ets 
transcription factors GAbp, which stands for “GA binding protein”, is an example of 
such a protein. While GAbpα contains an Ets DNA binding domain, a variant of the 
winged-helix-turn-helix motif, the transcriptional activation domain resides on GAbpβ, 
a Notch-related protein containing several ankyrin repeats at its N-Terminus (Figure 5). 
The activity of transcription factors can be either regulated by expression or indirectly 
through cell signalling. As mentioned earlier, the activity of the transcription factor GR 
is for instance activated by binding of its ligand. In this case, ligand binding and 
transcriptional activation are two functions of the same protein, a feature which all 
nuclear receptors share. The activity of the remaining classes of signal dependent 
transcription factors is also regulated by extracellular signals, yet, in these cases, the 
signal binds to a membrane-receptor thereby inducing intracellular signal pathways. 
These pathways and the gene expression changes they induce play a crucial role for the 
functional integrity of certain tissues. For example, a crucial function of the 
transcription factor GAbp in muscle tissue is to activate transcription of sub-synaptic 
targe genes, as for instance the epsilon-subunit of the AChR (AChRε). Congenital 
myasthenic syndrome, a muscular disorder affecting the NMJ, is correlated with a 
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mutation in the Ets-binding site of the AChRε promoter region thus underlying the 
importance of a functional gene expression for the integrity of muscle tissue (Ohno et 
al. 1999). 
 
Figure 5: Binding of the heterotetrameric GAbp protein (α2β2) to DNA sequences containing two 5´-
GGA-3´ cores. GAbpα (yellow) binds via its Ets domain directly to the DNA. GAbpβ (green) binds via 
its ankyrin repeats to GAbpα and heterodimerizes throught its Leucine Zipper domain. In addition, the 
pointed (PNT) domain of GAbpα and Ankyrin repeats and Leucine Zipper of GAbpβ can undergo further 
protein-protein interactions to proteins of the basal transcription machinery (Modified illustration by K. 
Sutliff for Science, Science 13 February 1998:Vol. 279. no. 5353, pp. 1000 - 1002) 
 
1.5 Aim of this study 
The aim of this study was to identify novel transcriptional regulators with dysregulated 
transcriptional activity in response to atrophic stimulation. Furthermore, the analysis of 
the underlying molecular mechanism of a dysregulated transcription factor and its 
impact on gene transcription in muscle cells was focus of interest. 
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2 Methods 
 
2.1 Cell Culture  
 
2.1.1 Cultivation of Mammalian Cells 
All cell lines were kept in incubators at 37°C, 95% humidity, and an atmosphere of 5% 
CO2.  
The murine muscle cell line C2C12 was grown in growth medium (GM). Cells were not 
allowed to reach confluency and passaged at ~ 60% confluency by trypsinization (3 mL 
per 15 cm plate). The detachment of cells occurred within 5 min at 37°C and was 
monitored by microscopic analysis. The reaction was stopped by addition of 9 mL GM 
and cells were pelleted by centrifugation (4 min, RT, 2500 rpm). The cell pellet was 
resuspended in GM (dilution 1:20 -1:30) and the cells seeded on fresh tissue culture 
dishes. C2C12 cells were used for a maximum of 10 passages. The differentiation of 
C2C12 myoblasts into myotubes was induced by serum withdrawal. Upon reaching > 
95% confluency, the growth medium was replaced by differentiation medium and 
replaced every 48 h during the course of differentiation. 
HEK293 and HEK293T cells were grown in DMEM supplemented with 10% FCS and 
1% P/S. For passaging, cells were rinsed off the plate by pipetting up and down and 
diluted as described for C2C12 cells.  
HEK293FT cells were also cultivated in DMEM supplemented with 10% FCS and 1% 
P/S. In addition, the medium was supplemented with 500 µg/mL Geneticin, 0.1 mM 
MEM Non-Essential Amino Acids, 1 mM Sodium Pyruvate, and 6 mM L-glutamine. 
Passaging of HEK293FT cells was performed as described for HEK293T cells.  
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RAW 264.6 cells, a mouse leukaemic monocyte macrophage cell line, were also kept in 
DMEM supplemented with 10% FCS and 1% P/S and cultivated as described with 
C2C12 cells.  
2.1.2 Thawing and Freezing of Cell Lines 
For preservation, tissue culture cell lines were stored in liquid nitrogen. The cells were 
washed once with PBS and collected by centrifugation (5 min at 2500 rpm). Then the 
cell pellet was resuspended in 1 mL freezing medium and the solution transferred 
directly into a cryovial. The cryovials were then positioned into a freezing device, 
which had been filled with isopropanol, thus allowing relatively slow freezing rates of ~ 
1°C per minute upon transfer to a -80°C freezer. After overnight incubation the 
container had reached -80°C, so that the cryovials were transferred to the liquid nitrogen 
tank for long term storage. 
For thawing cells, cryovials were removed from the liquid nitrogen tank and incubated 
immediately after in a 37°C water bath by slow agitation for 30 sec. 1 mL of appropriate 
growth medium was then applied to the vial and the cells were resuspended by pipetting 
up and down. Finally, the cell slurry was seeded on a fresh tissue culture dish containing 
pre-warmed growth medium. 
Dish format Area / well [cm2] Total area [cm2] 
10 cm - 55 
6-well plate 9.6 57.6 
12-well plate 3.8 45.6 
24-well plate 1.9 45.7 
Table 1: Tissue culture dish formats used for transfection and corresponding area per well. 
 
2.1.3 Generation of Conditioned RAW-Medium 
Generation of conditioned RAW-medium was performed by seeding 20 x 106 cells on 
individual 15 cm dishes. These cells were cultivated for 48 h. On day 3, the cells had 
reached ~ 95 % confluency and were stimulated for 6 h with 100 ng/mL 
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Lipopolysaccharides (LPS) in growth medium. Such generated medium was collected 
and stored at -20°C. Prior to use, the medium was centrifuged (3 min at 2500 rpm) and 
the supernatant 0.45 µm filtered. 
2.1.4 Transfection of Mammalian Cells  
In this study, two different cell lines were used for transfection studies. Due to the 
different transfection efficiency of HEK and C2C12 cells, two different transfection 
protocols were employed. 
2.1.4.1 Calcium Phosphate Transfection of HEK293(T) Cells 
For efficient transfection of HEK293 and HEK293T cells, the “Calcium Phosphate 
Transfection” protocol was employed as follows. The day before transfection, cells 
were seeded at a density of 2x 104 cells per cm2 dish surface. For overexpression studies 
cells were cultivated and transfected on 6-well plate format. In this context, cells were 
transfected with 2-3 µg DNA per well on 6-well plate format (2.6.3). In the course of a 
one-hybrid assay, 12-well plates were used instead and a maximum of 1.5 µg DNA was 
transfected per well. The DNA for transfection was mixed in an appropriate volume of 
0.25 M CaCl2 followed by adding an equal volume of 2x BBS and inverting the tube 
containing the reaction mix several times. The total volume of such generated DNA-
Calcium Phosphate Mix corresponded to 10% (v/v) of the medium volume per well in 
transfection. For instance, provided a 12-well plate was used with 1 mL medium per 
well, the respective DNA was diluted in 50 µL CaCl2, followed by addition of 50 µL 2x 
BBS. The DNA-Calcium Phosphate Mix was incubated at RT for 15 min and then 
added drop-wise to each well containing complete growth medium. The transfection 
was allowed to proceed for 8-16 h and was stopped by aspirating off the medium and 
replacement with new medium. 
2.1.4.2 Lipofectamine-Mediated Transfection of C2C12 Cells 
Since C2C12 cells were not efficiently transfected by using the “Calcium Phosphate 
Transfection” protocol, a Lipofectamine-mediated transfection was chosen instead and 
performed as follows. The day before transfection, cells were seeded at a density of 20x 
104 cells/well on a 12-well plate format. The next day, 3.3 µg/cm2 (here: 12.6 µg) 
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Lipofectamine were diluted in 25 µL Opti-MEM I. The DNA was diluted in 25 µL 
Opti-MEM I per well in a separate tube. The DNA and Lipofectamine solutions were 
then mixed and incubated at RT for 30 min. Finally, 350 µL serum-free DMEM was 
added to the DNA-Lipofectamine mix per well and the final mix applied a tissue culture 
well. The transfection was allowed to occur over 6 h in the incubator. Thereafter, cells 
were washed once with serum-free DMEM and differentiated by switching to DM. 
2.1.5 Stimulation of Mammalian Cells 
Cells were stimulated in complete growth medium by aspirating off the medium and 
replacing it with medium supplemented with corresponding stimuli. The duration of 
stimulation as well as final concentration of stimuli are indicated in the Results section. 
The various stimuli used in this study are listed in the Materials section. 
2.1.6 Mammalian One- and Two-Hybrid Assay 
For Mammalian One- and Two-Hybrid assays in HEK293T cells, the cells were seeded 
on 12-well plate formats, and transfected with 400 ng Gal4-Luc, 50 ng CMV-ß-gal, and 
400 ng Gal-X per well (2.1.4). On the next day, cells were stimulated for 24h (2.1.5), 
harvested (2.6.5) and targeted to luciferase- and ß-galactosidase-assays (2.6.7, 2.6.8). 
For transfection of C2C12 cells in the course of a mammalian one- or two-hybrid assay, 
100 ng Gal4-Luc, 20 ng CMV-ßGal and 100 ng Gal4-X or 1-5 ng Gal4-X and 1-5 ng 
Vp16-X were used for transfection (2.1.4). When using domain truncations of Gal4-
GAbpα (dOST, dPNT, dT280, dEts) and Vp16-GAbpβ (dLeuZip, dTAD, dPhoSit) in a 
mammalian two-hybrid assay, 50 ng of these deletions constructs were used. All other 
plasmids were used as described before in these assays.  
2.1.7 3xNBox and AChRε-Promoter Assays in C2C12 Cells 
For analysis of AChRε promoter activity in C2C12 cells, which were seeded on 12-well 
plate format, C2C12 myoblasts were transfected with 20 ng CMV-ßGal, 100 ng 
pCDNA3.1(-)GAbpα, 100 ng pCDNA3.1(-)GAbpβ and 200 ng pGL3, pGL3-AChRε or 
pGL3-AchRε-NBoxmut. Analysis of 3xNBox promoter activity in C2C12 cells was 
performed without co-expression of GAbp. The next day, cells were stimulated in DM 
with 5 nM NRG (human NRG-β1/HRG-β1 EGF domain) or vehicle (PBS + 0.1% BSA) 
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in the presence or absence of cytokine for 48 h (2.1.4, 2.1.5). Finally, cells were assayed 
for relative luciferase activity (2.6.5, 2.6.7, 2.6.8). 
2.2 Cell-Based High-Throughput Screen 
 
2.2.1 Reverse Transfection of HEK293T Cells 
In this study a library of transcriptional regulators was used that had been cloned in 
frame with an N-terminal Gal4 DNA-binding domain. This library had been spotted 
beforehand on individual 384-well plates (10 ng DNA/well). On the day of transfection, 
the control plasmids (Gal4, Gal4-GR, Gal4-p65, and Gal4-Vp16) were spotted on 
corresponding wells of each 384-well plate (10 ng/well). Then, the reporter construct 
Gal4-Luciferase (20 ng/well) was diluted in serum-free DMEM. This mix was 
supplemented with transfection lipid (100 ng/well corresponding to a ratio of 2.5:1) and 
the DNA-Lipid complexes were allowed to form within 5 min at RT. Using a 
“Multidrop 384” apparatus, 20 µL of this DNA-lipid mix were then added to each well. 
The HEK293T cells were collected from 15 cm dishes, diluted accordingly, and finally 
added to each well (9500 cells per well) for reverse transfection. These plates were then 
covered and incubated overnight at 37°C. 
2.2.2 Stimulation of Transfected HEK293T Cells 
The next day, cells were stimulated with vehicle (here: ethanol), 1 µM Dexamethasone, 
100 ng/mL human TNF-α, or both stimuli together for 24 h at 37°C. 
2.2.3 Luciferase-Assay 
Following stimulation, cells were lysed by addition of 40 µL BrightLite (PerkinElmer) 
reagent per well. Directly after, the luciferase-assay was performed on a “PerkinElmer 
(Wallac) 1430 ultraHTS microplate Imager ViewLux Station”. For each individual 
factor of the Gal4 library, the fold change was calculated over vehicle treatment. 
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2.3 Bacterial Culture Methods 
 
2.3.1 Cultivation of Bacteria 
Transformed E.coli cells were grown either in LB medium or on LB agar plates 
supplemented with antibiotics (50 µg/mL ampicillin, 50 µg/mL kanamycin, 30 µg/mL 
chloramphenicol). All plasmids from the Gal4 screen were amplified in E.coli grown in 
low salt LB medium supplemented with 25 µg/mL zeocin. 
2.3.2 Electroporation of Electrocompetent E.coli XL1-blue  
Electrocompetent E.coli XL1-blue cells were prepared routinely by technicians. For 
amplification of plasmid DNA, electrocompetent XL1-blue cells were used for 
electroporation. Initially, an electroporation cuvette was pre-chilled on ice. After 
thawing 50 µL of the electrocompetent cells on ice, 200 - 400 ng of plasmid DNA or 1 
µL of a ligation mix were added to the bacteria and the solution mixed by pipetting up 
and down. Upon transfer of the mix into a cuvette, a brief pulse of 2.5 kV was applied 
using the “Gene Pulser II”. Following this, the mix was supplemented with 300 µL of 
chilled LB medium and transferred to a reaction tube for a 30 min incubation step at 
37°C while shaking (650 rpm). Finally, 100-300 µL of such electroporated E.coli cells 
were plated on antibiotic-selective LB agar plates and incubated overnight at 37°C. 
2.3.3 Inoculation of E.coli 
Growth medium for E.coli (e.g. LB, NZY) was supplemented with antibiotic directly 
before use. Thereafter, a fresh overnight colony of E.coli was picked from an agar plate 
and transferred to 4 mL or 200 mL growth medium for mini- or maxi-preparation of 
plasmid DNA. Cells were grown overnight (14 - 18 h) under vigorous shaking at 37°C. 
2.4 DNA Methods  
 
2.4.1 Isolation of Genomic DNA 
Genomic DNA was extracted from mouse tissue as follows. About 20 mg of tissue were 
cut on dry ice at 4°C and transferred to pre-chilled 2 mL-tube containing steal beads on 
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dry ice. Homogenization of tissue was achieved by using the tissue lyser for 2 min 
(pulse frequency set to 30 Hertz). The sample was vortexed and allowed to chill for 5 
min at RT and supplemented with 0.5 mL lysis buffer for genomic DNA extraction. 
Proteinase K was added to the buffer directly before use. The proteins were digested for 
3 h at 60°C while shaking. Next, the tissue lysate was incubated under shaking at 56°C 
overnight. The next day, genomic DNA was extracted by two successive extraction 
steps with a 25:24:1 solution of Phenol: Chloroform: Isoamylalcohol (PCI). After 
adding 0.5 mL PCI to the cell lysate, the reaction tube was vortexed, centrifuged (10 
min, 4°C and 13,000 rpm), and the supernatant was transferred to a new tube. The next 
extraction step was performed with 0.5 mL Chloroform. The supernatant was again 
transferred to a fresh tube, followed by adding 0.5 mL Isopropanol and precipitating the 
genomic DNA for 1 h or overnight at -20°C. The genomic DNA was collected by 
centrifugation (45 min, 4°C and 13,000 rpm) and the supernatant discarded. The pellet 
was washed with 1 mL 75% Ethanol and centrifuged again (15 min, 4°C and 13,000 
rpm). Finally, the pellet was air-dried for 10 min and resuspended in 100 - 200 µL TE 
buffer. In order to complete resuspension, the reaction tube containing the DNA-pellet 
was incubated for 2 h at 60°C. Genomic DNA was stored at 4°C. 
2.4.2 Polymerase Chain Reaction 
 
2.4.2.1 PCR for Cloning 
Amplification of DNA in the course of a cloning procedure was routinely performed by 
PCR. Templates, primers and resulting plasmids are listed in the Materials Section. The 
Phusion polymerase was used routinely and each PCR reaction with a total volume of 
50 µL was composed of following components: 1x Phusion Buffer, 200 µM dNTPs, 10-
100 ng template DNA, 1 µM of sense and antisense primer, 0.01 U Phusion DNA 
polymerase. 
The initial denaturation was routinely performed for 3 min at 98°C followed by DNA-
amplification during 20-25 cycles of denaturation (10 sec 98°C), annealing (30 sec, Ta 
primer dependent) and elongation (time/kb, 72°C). Final elongation at 72 °C occurred 
over 10 min. Thereafter, 5-10 µL per PCR reaction were analyzed on an agarose gel. 
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2.4.2.2 Real-Time Quantitative PCR 
In order to quantify mRNA from mammalian cells or muscle tissue samples, the 
complementary DNA (cDNA) was targeted to real-time quantitative PCR (qRT-PCR). 
In this study, the TaqMan-Method (Livak et al. 1995) was employed. 
The cDNA samples obtained as described in paragraph 2.4.9 were diluted 10-fold with 
DNase/RNase free water. Per reaction 5 µL of such diluted cDNA was used. In 
addition, each reaction mixture was supplemented with 10 µL Platinum® Quantitative 
PCR Supermix, 0.4 µL ROX dye, 3.6 µL DNase/RNase free water and 1 µL of a 
specific TaqMan-Probe (see Materials Section). The subsequent PCR was performed 
routinely in duplicates for each gene of interest and in triplicates for housekeeping 
genes (TBP, GAPDH). GAPDH was used as housekeeping gene for the relative 
quantification of mRNA levels in gastrocnemius muscle samples of Colon26 mice. In 
all other experiments, TBP was used instead. All PCR reactions were pipetted on a 96-
well plate and the PCR was run on a “7300 Real Time PCR System”. The thermal 
profile consisted of an initial heating step at 50°C for 2 min followed by initial 
denaturation for 2 min at 95°C. Thereafter, DNA was amplified during 40-45 cycles of 
denaturation at 95°C (15 sec) and annealing/elongation at 60°C. Data acquisition took 
place in the annealing/elongation step. 
2.4.3 Restriction Digest of DNA 
In the course of a cloning procedure a preparative restriction digest of DNA fragments 
was performed. After Mini- or Maxi-Preparation of plasmids and prior to sequencing, 
the identity of DNA was routinely confirmed by an analytical restriction digest. 
Usually, 3-6 units of each restriction endonuclease were used per 10 µL batch volume 
and ~ 500 ng of DNA. The restriction digest was performed in a suitable restriction 
enzyme buffer and 1x BSA for 1.5 – 2 h at 37°C. Following this, the presence and size 
of DNA fragments was analyzed by agarose gel electrophoresis (2.4.5). 
METHODS 
 
 
31 
2.4.4 Purification of DNA  
DNA fragments resulting from PCR reactions for cloning were purified by using the 
“QIAquick PCR Purification Kit”1. In contrast, DNA fragments from restriction digests 
were purified over preparative agarose gels and subsequent use of a gel extraction kit. In 
the latter case, the total restriction digest reaction volume was supplemented with 1x 
Orange G DNA loading buffer, loaded onto a 1% agarose gel and DNA fragments were 
separated while applying 100 V for ~ 45 min to the gel. DNA fragments were then 
isolated from agarose gels by employing the “QIAquick Gel Extraction Kit” (for details, 
see manufacturers instruction). 
2.4.5 Agarose Gel Electrophoresis of DNA 
Following restriction digest or PCR, the DNA fragments were analyzed by gel 
electrophoresis. Agarose gels of suitable density (0.7 – 2 %) were poured in TBE buffer 
supplemented with 0.1 µg/ mL Ethidium Bromide. Orange G DNA loading buffer was 
then added to the DNA batches and samples were loaded to the hardened agarose gel. 
The DNA fragments of various sizes were resolved while applying a current of 100 V to 
the agarose gel and afterwards visualized in the “BioRad Gel Doc apparatus”. 
2.4.6 Determination of DNA Concentration 
The DNA concentration was determined spectrophotometrically by using the NanoDrop 
Spectrophotometer. Thereby, the ratio of absorptions 260nm/280nm was also analyzed. 
A ratio of 1.92-2.00 indicated relative low protein impurities (0-30%). 
2.4.7 Ligation of DNA Fragments  
In the course of a cloning procedure, the vector and insert, which had been digested to 
obtain compatible ends, were ligated as follows. Usually, 250 ng vector DNA and a 3-5 
fold molar excess of insert was used. Both, insert and vector, were mixed and the 
resulting volume was filled up with water to 10 µL. The DNA mixture was incubated 
for 5 min at 45°C and then chilled at RT. Afterwards, 2 µL 10x ligase buffer, 7 µL H2O, 
and 1 µL T4-DNA ligase were added to obtain a total ligation volume of 20 µL. The 
                                                 
1 For details, see manufacturers instruction 
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reaction was allowed to proceed for 2 h at RT followed by incubation for 14 - 16 h at 
4°C. Finally, 1 µL of the ligation mix was used for electroporation into 
electrocompetent XL1-blue E.coli cells. 
2.4.8 Preparation of Plasmid DNA 
In the course of a cloning procedure, plasmid DNA was usually prepared by using the 
“QIAprep Spin Mini Prep Kit”, while the “PureLink HiPure Plasmid Maxi Kit” was 
employed for obtaining larger amounts of plasmid DNA e.g. for transfection etc. 
2.4.9 Synthesis of Complementary DNA 
Complementary DNA (cDNA) was synthesized using the “First Strand cDNA Synthesis 
Kit”1. Usually, 1 µg of total RNA were used per cDNA reaction. 
2.4.10 Dephosphorylation of Plasmid DNA 
In the course of a cloning procedure, recircularization of vector DNA was minimized by 
dephosphorylation with the calf intestine phosphatase (CIP). The reaction containing 30 
µL DNA template, 4 µL 10x NEB3 buffer, 1µL CIP, and 5 µL water was allowed to 
occur for 1 h at 37°C. 
2.4.11 Sequencing of Plasmid DNA 
The sequence of plasmid DNA was routinely analyzed by the AGOWA company and 
the presence of the correct nucleotide sequence was confirmed by sequence alignment 
using the Vector NTI software from Invitrogen. 
2.4.12 Cloning of Plasmid DNA 
The insert of interest was obtained by either restriction digest or PCR amplification 
from the template plasmid DNA (2.4.2), template cDNA pool or genomic DNA. The 
PCR product was confirmed subsequently via agarose gel electrophoresis (2.4.5). Next, 
the insert and the vector were digested in parallel with the respective restriction 
enzymes (2.4.3). Such generated DNA fragments with compatible restriction sites were 
isolated by preparative agarose gel electrophoresis (2.4.5) and gel extraction (2.4.5). 
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The DNA fragments were then ligated (2.4.7) and electroporated (2.3.2) into 
electrocompetent XL1-blue E.coli cells. Isolated colonies were picked and transferred to 
LB medium for amplification of plasmid DNA (2.3.3). Following mini-preparation of 
plasmid DNA (2.4.8), the presence and the sequence of the insert were confirmed by 
restriction digest and sequencing (2.4.11). 
2.5 RNA Methods 
 
2.5.1 Preparation of RNA from Tissue Culture Samples  
All steps were performed routinely at RT using columns and buffers from the “RNeasy 
Mini Kit”. Initially, cells were harvested in RLT buffer (300 µL per well on a 6-well 
plate format) supplemented with 1% ß-mercaptoethanol. Alternatively, cells were lysed 
in QIAzol and RNA purified by chloroform extraction. The cell lysate was then 
transferred to the - 20°C freezer for further storage, or loaded directly after on a 
QIAshredder column and centrifuged (13,000 rpm, 2 min). The eluate from this initial 
centrifugation step was mixed with an equal volume of 70% ethanol by pipetting up and 
down. The resulting reaction mixture was then transferred to an RNeasy column and 
centrifuged again (13,000 rpm, 1 min). After discarding the flow-through, the column 
was washed with 350 µL RW1 buffer by applying the buffer on the column and 
incubating the column for 5 min at RT. This step was directly followed by a 
centrifugation step (13,000 rpm, 1 min). Next, on-column-DNA-digestion was 
performed as follows: 15 µL DNase was gently mixed in 105 µL DNase buffer (RDD 
buffer) and then applied to each column. The reaction was allowed to proceed for 22 
min at RT. Subsequently, 350 µL RW1 buffer were added to each column and 
incubated for 2 min. The column was finally washed twice with 500 µL RPE buffer and 
the RNA eluted in 30 µL of RNase free water. RNA was stored at -80°C.  
2.5.2 Preparation of RNA from Mouse Muscle Tissue Samples 
All steps involving handling with phenol reagents such as QIAzol were performed 
under a fume hood. At the beginning, tissue samples were cut on dry ice inside the cold 
room (4°C) into pieces of 30-60 mg. Such generated tissue samples were transferred to 
pre-chilled 2 mL tubes containing single strainless steal beads and 1 mL QIAZOL on 
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dry ice. Homogenization of tissue was achieved by using the tissue lyser for 2 min 
(pulse frequency set to 30 Hertz). The samples were vortexed and incubated for 5 min at 
RT. The RNA was purified by adding 0.2 mL chlorophorm to each tube and vigorous 
shaking at RT for 15 sec. Following an additional incubation time on ice for 5 - 10 min 
(until phase separation was visible), the tubes were centrifuged for 15 min at 4°C and 
13,000 rpm. As next, the aqueous phase was transferred to a new tube and 
supplemented with 0.6 mL 75% ethanol. Finally, the reaction was mixed thoroughly, 
applied to an RNeasy column and RNA preparation continued as described in 2.5.1. 
2.5.3 Determination of RNA Concentration 
The RNA concentration was determined spectrophotometrically at 260 nm using the 
NanoDrop Spectrophotometer. In parallel, the ratio 260 nm/280 nm was detected in 
order to measure protein-impurities in the samples (see 2.4.6). 
2.5.4 Agarose Gel Electrophoresis of RNA 
In the course of RNA preparation from tissue culture and muscle tissue samples, the 
quality of the RNA was routinely analyzed by agarose gel electrophoresis. 1% agarose 
gels were poured with RNase-free agarose in 1x TBE buffer. The RNA samples were 
denatured in a formaldehyde/formamide solvent (RNA denaturing buffer). If not else 
mentioned, 1 µL per RNA sample were added to 10 µL RNA denaturing buffer and 
incubated for 10 min at 65°C. As next, the total volume (11 µL) was loaded onto the 
agarose gel and separated for at least 40 min at 100 V. The quality of the RNA was 
determined visually by examination of the ratio between 28S to 18S ribosomal RNA, 
which was 2:1 for intact RNA. 
2.6 Protein Methods  
 
2.6.1 Determination of Protein Concentration 
For determination of protein concentration, two different methods were employed. 
Provided the cell lysate was prepared with the 2x SDS + 8 M Urea buffer, the protein 
content of such obtained denaturing protein extracts was determined by using the “2-D 
Quant Kit”. For this purpose, the proteins were precipitated and then targeted to an 
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absorption detection method. If, however, a native cell extract was prepared, the 
Bradford Assay was employed instead. The Bradford reagent was diluted 5-fold in 
water and 1 mL of such generated solution added to each single plastic cuvette. Then, a 
suitable volume of cell lysate (3-5 µL) was added to a cuvette and the solution 
subsequently mixed. The absorption of the various cell lysate samples was measured in 
a Spectrophotometer at a wavelength of 595 nm. In parallel, a BSA standard curve was 
determined, encompassing the range of ~ 5 - 20 µg protein. 
2.6.2 SDS-Polyacrylamide Gel Electrophoresis of Proteins  
For SDS-PAGE analysis of proteins, denaturing SDS gels were used. Usually, 15%, 
10% or 8% resolving gels were poured in order to separate and analyze proteins of 10-
60 kDa, 30-120 kDa or 50-200 kDa. In all cases, a 4% stacking gel was poured on top 
of the resolving gel. Proteins were denatured in SDS Reducing buffer and boiled at 
95°C for 5-10 min. Finally, 10-50 µg protein was loaded per lane. As protein mass 
standard, 5 µL of the “PageRuler™ Unstained Protein Ladder” were used. The protein 
samples were allowed to enter the stacking gel while applying 100 V. As soon as the 
samples have entered the resolving gel, the current was increased up to 150 V. 
2.6.3 Western-Blot 
Proteins, which had been resolved by SDS-PAGE, were electrophoretically transferred 
to nitrocellulose membranes using the Wet-Blot principle for subsequent analysis of 
protein expression. Prior to use, the membrane was equilibrated for ~ 20 min with 
transfer buffer. All other components of the blotting apparatus, as for instance sponges, 
filter papers, and the gel, were also pre-chilled in transfer buffer. The efficient transfer 
of proteins was achieved by applying a current of 30 V to the apparatus at 4°C and 
overnight. 
The expression of proteins was analyzed by Western-Blot. Following overnight 
blotting, the nitrocellulose membrane was rinsed in water and the protein transfer was 
confirmed by Ponceau S staining. The staining solution was then removed and 
unspecific antigen sites blocked by incubating the membrane under mild agitation for 1 
h in blocking buffer. The primary antibody was diluted to the desired final 
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concentration (see Materials Section) in blocking buffer and the membrane incubated 
with the primary antibody for 1 h under mild agitation. Subsequently, the membrane 
was washed three times for 10 min with PBS-T buffer. The secondary antibody, a 
Horseradish Peroxidase (HRP) conjugate, was diluted likewise (1:3000 – 1:5000) and 
allowed to bind to the primary for 1 h under mild agitation. Again, the membrane was 
washed three times for 10 min with PBS-T buffer and incubated directly after with the 
“ECL™ Western Blotting Detection Reagents”. The chemiluminescent reaction of the 
enzyme Horseradish Peroxidase was monitored on “Hyperfilm™ ECL” films.  
2.6.4 Co-Immunoprecipitation of Proteins from C2C12 Cells 
The C2C12 cells, destined for immunoprecipitation (IP) of endogenous proteins, were 
washed twice with ice-cold PBS on ice. Then, 0.5 mL of Larry-buffer was added per 10 
cm dish and the cells were scraped off the plate. The cell slurry was transferred to a 
reaction tube and incubated on ice for 30 min. Every 5-10min, the reaction tube was 
vigorously vortexed in order to enable complete cell lysis. Thereafter, the cell debris 
was collected by centrifugation (15 min, 4°C, and 13,000 rpm). The supernatant was 
transferred into a new tube, thereby keeping an aliquot as input in a separate tube. The 
immunoprecipitation of endogenous proteins from the cell lysate was performed for 1 h 
on ice by using 1 µg of the respective antibody. Meanwhile, Protein A/G PLUS-
Agarose (25%) was equilibrated in cell lysis buffer by two subsequent washing and 
centrifugation steps (5 min, 4°C and 2,500 rpm) and added to the antibody-cell lysate 
(final concentration: 4% of the total reaction volume). Such generated mix was allowed 
to rotate mildly at 4°C for 1 h. The agarose was collected thereafter by centrifugation (5 
min, 4°C and 2,500 rpm). An aliquot of this first centrifugation step was kept as 
unbound protein fraction. The agarose was then subjected to three consecutive washing 
and centrifugation steps (5 min, 4°C and 2,500 rpm). At the end of the IP, 40-50 µL of 
2x SDS reducing buffer were added to each tube in reaction and proteins denatured by 
boiling at 95°C for 5 min. The tubes were vigorously vortexed, centrifuged (5 min, RT 
and 13,000 rpm), and the supernatant was carefully transferred to a new tube. These 
eluates were finally separated by SDS-PAGE (2.6.2). Likewise, previously collected 
input and unbound protein fractions were diluted in an equivalent volume of 2x SDS 
reducing buffer and boiled for 5 min. 20 µL of each fraction were loaded onto SDS gels. 
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2.6.5 Harvesting Cells for Reporter-Assay 
In the course of a promoter analysis or a mammalian one- or two-hybrid assay, 
accordingly transfected and stimulated cells were harvested from 12-well plates for 
subsequent determination of luciferase- (2.6.7) and ß-galactosidase-activity (2.6.8). The 
cells were washed once with PBS and then lysed in 0.15 mL harvest buffer by mildly 
agitating the multi-well plates for 5 min. The cell slurry was then transferred to a 
reaction tube and the cell debris collected by centrifugation for 5 min at 4°C and 13,000 
rpm. Finally, the supernatant was used for determination of luciferase- and ß-
galactosidase activity (2.6.7, 2.6.8). 
2.6.6 Western-Blot Analysis of Proteins from Cell Culture Extracts 
For Western-Blot analysis of overexpressed protein levels in cell culture extracts whole 
cell extracts (WCE) were prepared. If not else mentioned, cells were grown on a 6-well 
plate format and harvested in 0.3 mL buffer per well. Denaturing WCE for protein 
analysis were prepared by washing cells once with 1x PBS and lysing the cells on the 
plate in 2x SDS + 8 M Urea buffer. Immediately after, the samples were boiled for 10 
min at 95°C. The concentration of these extracts was subsequently determined via “2-D 
Quant Kit” and the extracts stored at -20°C until further analysis. Provided, endogenous 
protein levels were analyzed, native or whole cell extracts were prepared. Thereafter, 
the protein content was determined (2.6.1) and 10 – 20 µg protein resolved via SDS-
PAGE (2.6.2). Finally, the protein expression was analyzed by Western-Blot by using 
appropriate antibodies (2.6.3). 
2.6.7 Assay for Luciferase Activity 
Luciferase activity was routinely analyzed in the course of mammalian one- and two-
hybrid or promoter assays. The assay was performed in triplicates on 12-well plates. 
The amount of luciferase correlated to the promoter activity and was determined by an 
enzymatic assay. Usually, 30 µL of cell lysate (see 2.6.5) were used per well. The cell 
lysates containing the luciferase enzyme were pipetted on a black 96 well plate. Prior to 
measurement, 100 µL assay buffer containing co-factors required for the reaction were 
added to each well. The plate was then loaded into the Luminometer and luciferase 
activity measured upon injection of 100 µL Luciferase buffer, which contained the 
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substrate. The relative luciferase activity per reaction mixture was calculated relative to 
ß-Galactosidase activity (2.6.8) 
2.6.8 Assay for ß-Galactosidase Activity 
The activity of the reporter enzyme ß-galactosidase was determined via an enzyme 
activity measurement. Briefly, 50 µL of supernatant from cell lysates (2.6.5) were 
pipetted into individual wells of a translucent 96-well plate. Then, 50 µL of ONPG 
buffer containing the substrate were added to each well. The amount of ß-galactosidase 
in the cell lysate was proportional to the amount of transformed substrate. The latter is 
measured by an absorption measurement at a wavelength of 480 nm. 
2.7 RNAi Design and Cloning Methods 
The “Block-iT™ Pol II RNAi Expression Vector Kit” from Invitrogen was employed 
for cloning a miRNA GAbpα expression vector.  
2.7.1 Design of miRNAs Targeting Murine GAbpα 
For RNAi-mediated knock-down of GAbpα in C2C12 cells, the online available 
“Invitrogen´s RNAi Designer” was used to design three different miRNAs targeting the 
3’ UTR within GAbpα mRNA by use of following parameters. The sequences of the 
miRNAs are listed in the Materials Section. 
Gene Name GAbpα 
Organism Mus Musculus 
Definition GA repeat protein, alpha, mRNA 
Accession BC013562 NM 008065 
ORF Region 151-1206 447-1811 
Length 4266 5004 
Table 2: This table illustrates the parameters used for the design of miRNAs targeting the 3’ UTR 
within GAbpa mRNA by using the online available “Invitrogen´s RNAi Designer” software.  
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2.7.2 Cloning of the miRNA Expression Vectors 
An expression vector for the miRNA was cloned according to the “Block-iT Pol II miR 
RNAi Expression Vector Kits” by using the buffers and components included in the kit. 
Initially, the single-stranded DNA (ssDNA) oligos were reconstituted with water to a 
final concentration of 200 µM. Following this, the bottom and top oligo were annealed 
for each miRNA target position (1256, 4216, 4682) by mixing 5 µL of each top and 
bottom strand ssDNA oligo with 2 µL 10x OligoAnnealing Buffer and 8 µL 
RNase/DNase free water in a 0.5 mL sterile microcentrifuge tube at RT. The mix was 
then boiled for 4 min at 95°C. The annealing occurred during the successive chilling of 
the tubes for 5 – 10 min at RT. Such generated 50 µM stock solutions of double-
stranded DNA (dsDNA) oligos were then diluted via serial dilutions to 10 nM solutions 
with water and 10x oligo annealing buffer. The integrity of the dsDNA oligos was 
checked via gel electrophoresis on a 4% agarose gel. 
The ligation of the dsDNA oligos into the pCDNA6.2-GW/EmGFP vector was 
performed by mixing following components in the indicated order at RT: 
Component (stock concentration) Volume [µL] 
5x Ligation Buffer 4 
pCDNA6.2-GW/EmGFP (5 ng/µL) 2 
ds oligo (10 nM) 4 
H2O 9 
T4 DNA Ligase 1 
Table 3: This table summarizes the components required for ligation of the dsDNA oligos with the 
pCDNA6.2-GW/EmGFP vector. 
The ligation batch was mixed well by pipetting up and down, incubated at RT for 5 min 
and transformed into OneShot TOP10 competent E.coli. For chemical transformation, 2 
µL of the ligation mixture were added into one vial of TOP10 E.coli cells and gently 
mixed by pipetting up and down. The tube was incubated on ice for 20 min, followed by 
a heat-shock for 30 sec at 42°C and immediate transfer of the tube to ice. Following 
this, 250 µL of chilled SOC medium were added to the bacteria and the tube shaked at 
37°C for 1 h. Finally, the cells were plated on spectinomycin (50 µg/mL) selective agar 
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plates. The next day, single bacterial colonies were transferred into LB medium, grown 
overnight and subjected to plasmid-preparation (2.4.8). Plasmids were analyzed via 
sequencing. These miRNA expression vectors (pCDNA6.2-GW/EmGFP-miRNA) were 
tested thereafter using the pTarget system for knock-down efficiency of the target 
protein, GAbpα in vitro (2.7.4). 
2.7.3 Cloning of GAbpα into the pTarget Vector 
The validation of knock-down efficiency of miRNAs was performed by using the 
“GeneEraser™ Luciferase Suppression-Test System” by Stratagene. For this purpose, 
the Gabpα sequence containing the miRNA target site was cloned into the pTarget 
vector thus generating a fusion protein of Gabpα and the luciferase reporter. Here, a 
modified version of the pTarget vector containing a multiple cloning site (MCS) was 
used for cloning of the Gabpα DNA sequence. Two PCR reactions were performed to 
amplify two different Gabpα DNA sequences from a cDNA pool from C2C12 cells. For 
generation of the plasmid pTarget-GAbpα-ORF the forward primer GAbpα-pos447-for 
and the reverse primer GAbpα-pos2401-rev were taken. By using the primer pair 
GAbpα-pos2443-for and GAbpα-pos4767-rev, the plasmid pTarget-GAbpα-3’UTR was 
cloned. The PCR reactions were analyzed via agarose gel electrophoresis (2.4.5), 
purified (2.4.4) and digested - along with the vector - with NotI (2.4.3). Thereafter, the 
vector and inserts were resolved on a preparative agarose gel (2.4.5) and excised from 
the gel. Prior to ligation (2.4.7), the vector was dephosphorylated (2.4.10). The 
amplification of ligated vectors was performed in XL10-Gold ultracompetent cells: For 
each transformation, 40 µl of cells were transferred into a 15 mL polypropylene round-
bottom tube followed by adding 1.6 µL of the XL10-Gold β-mercaptoethanol mix to 
each batch of cells. The mix was gently swirled every 2 min during a total incubation 
time of 10 min on ice. Then, 2 µL of the ligation reaction were added, directly followed 
by a further incubation period of 30 min on ice. The tubes were heat-pulsed for 30 sec at 
42°C in a water bath and incubated thereafter for 2 min on ice. Finally, 0.45 mL pre-
heated NZY+ broth medium were added to each tube and the cells incubated in this 
medium for 1 h at 37°C while gently shaking (225 rpm). The cell slurry was spread on 
NZY+ broth agar plates containing 50 µg/ mL kanamycin. The next day, isolated 
colonies were picked and transferred to NZY+ broth medium for inoculation (2.3.3). 
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Following overnight amplification of E.coli, plasmid DNA was prepared (2.4.8), 
digested with NotI, BamHI, EcoRI or HindIII (2.4.3) and analyzed via agarose gel 
electrophoresis (2.4.5). Positive clones were further analyzed by sequencing. 
2.7.4 Validation of Knock-Down Efficiency of miRNAs with the 
“GeneEraser™ Luciferase Suppression System” 
Following the cloning of the miRNA expression vectors (2.7.2) and the pTarget- 
GAbpα vectors (2.7.3), the “GeneEraser™ Luciferase Suppression System” was 
employed to validate the knock-down efficiency of the three designed miRNAs (1256, 
4216, 4682) in vitro. The assay was performed on 24-well plates in HEK293 cells. Cells 
were transfected in triplicates with declining amounts (250, 100, 10 or 1 ng) of a 
negative control miRNA-expression vector (pCDNA6.2-GW/EmGFP-miRNA NC) or a 
Gabpα targeting miRNA-expression vector (pCDNA6.2-GW/EmGFP-miRNA 
1256/4216/4682). The plasmid CMV-β-gal was used at a final concentration of 25 
ng/well and the luciferase reporter gene plasmid was used at a final concentration of 
100 ng/well. The plasmid pTarget-Gabpα-3’UTR was taken for analysis of miRNA 
4216 and miRNA 4682, while pTarget-Gabpα-ORF was sued for analysis of miRNA 
1256. For each well in transfection, 25 µL CaCl2 and 25 µL 2x BBS were used 
(2.1.4.1). The next day, the transfection medium was aspirated off and replaced by new 
medium. The Luciferase- and ßGalactosidase-Assay (2.6.5) was performed 40 h after 
transfection start. 
2.7.5 Validation of the Knock-Down Efficiency of miRNA on 
Overexpressed Protein Levels 
The knock-down efficiency of the miRNA 1256 was assessed by overexpression along 
with a GAbpα expression vector in HEK293T cells. For this purpose, an overexpression 
vector for GAbpα containing the miRNA target site was required. The GAbpα sequence 
from the plasmid pTarget-Gabpα-ORF was obtainted via restriction digest with NotI 
(2.4.3) and cloned into the pCDNA3.1(-) vector. This overexpression vector for GAbpα 
was used for validation of knock-down efficiency of miRNA 1256 as well as for AChRε 
promoter assays (2.1.7). 
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HEK293T cells were seeded on a 6-multiwell dish (2.1.4.1). The next day, cells were 
transfected (2.1.4.1) with 2 µg pCDNA3.1(-)GAbpα overexpression plasmid per well. 
While one well was left untreated, four wells were concomitantly transfected with 
increasing amounts (0.5, 1, 2 and 4 µg) of the miRNA1256 expression plasmid 
(pCDNA6.2-miR1256). The last well was transfected with the highest plasmid amount 
used (4 µg) of an unspecific miRNA (pCDNA6.2-miRNC). The transfection medium 
was changed the next day and whole cell extracts were prepared 48 h after transfection 
start. The protein content of these prepared whole cell extracts was determined (2.6.1), 
30 µg total protein of each sample were resolved by SDS-PAGE (2.6.2). GAbpα 
expression was analyzed via immunoblotting (2.6.3). 
2.7.6 Cloning of a Lentiviral Destination Vector 
A lentivirus based gene transfer system was employed for RNAi delivery into C2C12 
cells. For the production of RNAi containing lentivirus, a lentiviral destination vector 
was required and cloned according to the “Block-iT™ Lentiviral Pol II miR RNAi 
Expression System” from Invitrogen.  
The pCDNA6.2-GW/EmGFP-miRNA1256 and pCDNA6.2-GW/EmGFP-miRNANC 
expression vectors contained attB sites, which could not be directly used with the 
pLenti6/V5-DEST destination vector to generate a lentiviral expression vector. Instead, 
a BP reaction was performed as follows in order to generate an entry clone containing 
attL sites. Initially, the pCDNA6.2-GW/EmGFP-miRNA1256/NC expression vectors 
were linearized using EagI: 6 µL of 1µg/µL expression vector were mixed with 2 µL 
10x BSA, 2 µL NEB3, 1.25 µL EagI, and 12.75 µL water and incubated for 90 min at 
37°C. Next, the linearized DNA was precipitated with 0.1 volumes of 3 M sodium 
acetate (here: 2 µL were used) and 2.5 volumes of 100% ethanol. The DNA pellet was 
pelleted by centrifugation (5 min, 13,000 rpm), washed twice with 70% ethanol, and 
dissolved in TE buffer. Subsequently, the actual rapid BP/LR Recombination Reaction 
was performed at RT as follows: 40 fmol of linearized attB expression clone 
(miRNA1256 or miRNANC), 150 ng pDONR 221 vector were mixed in TE buffer to a 
final reaction volume of 8 µL. Then, 2 µL of the BP Clonase II enzyme mix were added 
to this reaction, mixed well by pipetting up and down, and incubated for 1 h at 25°C, 
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thereby generating pENTR 221/miR1256 and pENTR 221/miRNC. Next, 3 µL from 
each BP reaction were transferred to a new sterile 0.5 mL microcentrifuge tube and 
filled up with 150 ng pLenti6/V5-DEST vector and TE buffer to a final reaction volume 
of 8 µL. Finally, 2 µL of LR Clonase II enzyme mix were added to the reaction and the 
reaction was allowed to proceed for 2 h at 25°C. Following this, 1 µL of the Proteinase 
K solution were added to each reaction and incubated for 10 min at 37°C. 
The LR recombination reaction was then transformed into “One Shot® Stbl3™ 
Chemically Competent E.coli”. For each transformation reaction, one vial of these cells 
was thawn on ice followed by adding 3 µL of the LR recombination reaction to the 
competent cells. The reaction was gently mixed and incubated for 30 min on ice. The 
heat-shock occurred for 45 sec at 42°C directly followed by chilling the reaction on ice 
for 2 min. Next, 250 µL of pre-warmed SOC medium were added and the tube 
incubated at 37°C for 1 h while shaking (225 rpm). Finally, the transformation mix was 
spread on ampicillin selective agar plates and incubated overnight at 37°C. Single 
putative expression clones were tested in parallel for ampicillin-resistance and 
chloramphenicol-sensitivity. Such obtained pLenti6/miRNC and pLenti6/miRGAbpα 
vectors were then used for production of Lentivirus in HEK293FT (2.8.1) or HEK293T 
cells (2.8.2). 
2.8 Lentivirus Methods 
 
2.8.1 Production of Lentivirus in HEK293FT Cells  
Two different Lentiviruses were produced here according to the “Block-iT™ Lentiviral 
Pol II miR RNAi Expression System” from Invitrogen. One lentivirus originating from 
plasmid NC contained the miRNA NC sequence while the other contained the miRNA 
GAbpα sequence. 
DNA-Lipofectamine 2000 complexes were prepared as follows for both transfection 
samples individually (Lentivirus miR NC or miR Gabpα): 9 µg ViraPower™ Packaging 
Mix and 3 µg pLenti6/miRNC or pLenti6/miRGAbpα were diluted and gently mixed in 
1.5 mL of Opti-MEM I medium without serum in a sterile 5 mL tube. In parallel, 36 µL 
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Lipofectamine™ 2000 were diluted in a separate 5 mL tube in 1.5 mL Opti-MEM I 
medium without serum, mixed, and incubated for 5 min at RT. Then, both, DNA and 
Lipofectamine™ 2000, were combined, again gently mixed, and incubated for 20 min at 
RT. Meanwhile, HEK293FT cells were collected and resuspended at a density of 1,2 x 
106 cells/mL in growth medium containing serum, yet without antibiotics. The DNA-
Lipofectamine™ 2000 complexes were added to a 10 cm tissue culture plate containing 
5 mL of growth medium containing serum without antibiotics. Next, 5 mL of the 
HEK293FT cell suspension were added to the plate, mixed gently by rocking the plate 
back and forth and incubated overnight at 37°C. The next day, the transfection medium 
was replaced by normal growth medium containing sodium pyruvate plus antibiotics. 
The virus-containing supernatant was harvested 48-72 h post-transfection by 
transferring the supernatant to a 15 ml falcon tube and collecting the cell debris by 
centrifugation for 5 min at 4°C and 3,000 rpm. The supernatant was 0.45 µm filtered, 
aliquoted, and stored at - 80°C. 
2.8.2 Production of Lentivirus in HEK293T Cells 
As alternative packaging cell, HEK293T cells were utilized for production of 
Lentivirus-miRNC and Lentivirus-miRGAbpα according to (Tiscornia et al. 2006). One 
day before transfection, HEK 293T cells were seeded on 10 cm tissue culture plates at a 
density of 3x 106 cells/dish. The next day, the medium was changed to 9 mL per 10 cm 
dish 1h prior to transfection. Per 10 cm dish, the following plasmids were mixed in a 
reaction tube in 0.5 mL CaCl2: 10 µg vector (pLenti6/miRNC or pLenti6/miRGAbpa), 
6.5 µg pMDL g/p RRE, 3.5 µg pMD2.G, and 2.5 µg pRSVrev. Then, 0.5 mL 2x BBS 
were added to the CaCl2-DNA mix and the transfection was continued as described in 
2.1.4.1. The next day (~ 12 h later), the medium was replaced by fresh medium and the 
virus-containing supernatant was harvested another 24-48 h later. The cell debris was 
collected by centrifugation for 5 min at 1,000 rpm and the supernatant was 0.45 µm 
filtered. For scale-up, the same transfection protocol was performed on 15 cm dishes 
with accordingly larger amounts of plasmids and transfection media. 
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2.8.3 Concentration of Lentivirus via Ultracentrifugation 
Lentivirus containing supernatant from HEK293T cells was concentrated via 
ultracentrifugation. Initially, the supernatant was centrifuged (2,500 rpm, 5 min, 4°C) 
and 0.45 µm filtered. Thereafter, the virus was collected via ultracentrifugation in 
ultraclear centrifugation tubes for 90 min at 25,000 rpm and 4 °C. The pellet was 
allowed to dissolve overnight at 4°C in 0.1 mL filtered (0.22 µM) PBS. The next day, 
aliquots were prepared and stored at -80 °C. 
2.8.4 Transduction of C2C12 Cells with Lentivirus 
C2C12 Sigma cells were transduced with lentivirus for titering of the lentiviral stock, 
assessment of knock-down efficiency or generation of stable knock-down clones. The 
transduction was performed either after or while cells were seeded on a 6-well plate 
format in 1-1.5 mL of GM. This transduction medium contained diluted lentiviral stock 
as indicated and was supplemented with 6 µg/mL polybrene. Provided that cells were 
transduced while being passaged, 3x 104 cells per well were added to each transduction 
batch. Untransduced cells served as control, hence named “mock”. 
2.8.5 Titering of the Lentiviral Stock in C2C12 Cells 
C2C12 cells were transduced on day 0 with lentivirus (2.8.4) by using a serial dilution 
of virus. The transduced cells were targeted to Blasticidin-selection (2-4 µg/mL) from 
day 4 on for ~ 10 days by changing the medium every 3-4 days. The medium was then 
aspirated off and cells were washed twice with PBS. For visualization of individual cell 
clone populations, 1 mL of crystal violet solution was added to each well. The cells 
were incubated for 10 min at RT, thereafter washed again twice with PBS and the 
stained colonies counted. 
2.8.6 Generating Stable miRNA Expression C2C12 Clones 
C2C12 cells were transduced on duplicate wells on day 0 with lentivirus as described 
under 2.8.4. Starting on day 3, efficiently transduced cells were selected with 
Blasticidin by supplementing GM with 2 µg/mL antibiotic. The medium was replaced 
by new medium every 3-4 days. On day 10 of selection, cells had reached ~ 70% 
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confluency and were passaged. For selection of monoclonal miRNA expression clones, 
cells were seeded on 96-well plate format with each well containing one cell clone. For 
generation of polyclonal miRNA expression clones, a cell pool was seeded on 10 cm 
dishes. The selection pressure was increased for the next 7 days by changing the 
antibiotic-concentration in GM to 4 µg/mL until all non-transduced cells on mock wells 
were killed. During selection for mono- and polyclonal miRNA expression C2C12 cells, 
cells were passaged and seeded on larger tissue culture dishes prior to reaching > 70% 
confluency. Finally, cells were allowed to differentiate into myotubes and tissue culture 
samples were prepared for mRNA (2.5.1) and protein (2.6.6) analysis. 
2.9 Colon26 Murine Cachexia Model 
For tumor induction in cachexia models, 1.5*106 Colon-26 cells in PBS were injected 
subcutaneously into 10-week-old CD2F1 mice (Charles River Laboratories, Brussels). 
Control mice were injected with PBS. Mice were sacrificed approximately 3 weeks after 
injection. 
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3 Results 
 
3.1 Identification of Novel Transcriptional Regulators with 
Altered Activity under Atrophic Signalling 
In this study, a cell-based high-throughput screen was employed in collaboration with 
M.D. Conkright from the Scripps Research Institute in Florida (USA) in order to 
identify novel transcriptional regulators being dysregulated under atrophic signalling. 
The screen consisted of ~ 1450 transcriptional regulators from human (755) and mouse 
(695) origin, which had previously been cloned in frame with an N-terminal Gal4 DNA-
binding domain (Gal4). Individual transcriptional regulators were transfected along with 
a GAL4 UAS::luciferase reporter construct into HEK293T cells (2.2.1).  
 
Figure 6: The cell-based high-throughput screen used in this study was based on the mammalian 
one-hybrid assay. Individual transcriptional regulators (TFx), which had been cloned in frame with an 
N-terminal Gal4 DNA-binding domain (Gal), were each transfected along with a GAL4 UAS::luciferase 
reporter (Gal4-Luciferase) into HEK293T cells. The screen consisted of ~ 1450 transcriptional regulators 
from human and mouse origin. 
Following transfection, the Gal4 fusion proteins would bind to the Gal4 promoter 
thereby activating transcription of the luciferase reporter gene. The amount of expressed 
luciferase is determined by the ability of individual fusion proteins to recruit 
endogenous proteins from the basal transcription machinery or other transcriptional 
regulators and activate thereby transcription. Thus, under these conditions, each fusion 
protein has a basal transcriptional activity which can be monitored by luminescence 
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measurement. The molecular mechanisms underlying this screen design is identical with 
a mammalian one-hybrid assay (Figure 6). 
Since the overall aim was, to find novel transcriptional regulators in two different in 
vitro models of muscle atrophy, cells were treated with TNF-α and Dex (2.2.2). These 
stimuli induced signal transduction pathways thereby changing the expression, 
localization or activity of endogenous proteins of the transcription machinery. Provided, 
these shift had an impact on individual Gal4 fusion proteins, the basal transcription 
activity of these Gal4 fusion proteins would either increase or decrease. Thus, focus of 
interest was to identify those transcriptional regulators with a significant change in 
relative luciferase activity upon pro-atrophic stimulation. Noteworthy, this screen 
design allowed monitoring changes in functional interactions between the Gal4 fusion 
protein and the proteins of the transcription machinery. 
3.1.1 TNF-α Caused the Strongest Changes in Transcriptional Activity 
In preparation for the actual screen, two Gal4 fusion proteins were validated as positive 
controls for the stimulation of cells with Dex and TNF-α, Gal4-GR and Gal4-NFKBIA, 
respectively. As negative control, the Gal4-DBD alone (Gal4) was used. Dex treatment 
induced significantly the transcriptional activity of Gal4-GR via the Gal4-Luc 
promoter-reporter construct (Figure 7). Thereby, a concentration of 1 µM Dex was 
sufficient and hence used for the screen. The fusion protein of Gal4 with IκBα (Gal4-
NFKBIA) served as an ideal positive control for stimulation with TNF-α, since TNF-α 
increased the transcriptional activity of this fusion protein dose-dependently (Figure 7). 
Due to the potent apoptotic side effects of TNF-α, the mid-range concentration of 100 
ng/mL TNF-α was chosen for the actual screen. In addition to the treatment with TNF-α 
or Dex, cells were also stimulated with both stimuli together in a third group, since the 
intracellular pathways induced by TNF-α and Dex are known to interact (McKay & 
Cidlowski 1999). Basically, the screen was performed as described in Amelio et al. 
2007 (2.2).  
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Figure 7: A concentration of 100 ng/mL TNF-α and 1 µM Dex was sufficient to induce relative 
luciferease activity of Gal4-NFKBIA and Gal4-GR, respectively. HEK29T cells were transfected with 
Gal4-Luc and CMV-ß-gal and Gal4-NFKBIA or Gal4-GR. Thereafter, cells were stimulated for 24 h with 
10, 100, or 200 ng/mL TNF-α or 1, 5, or 10 µM Dex. Finally, relative luciferase activity was assayed and 
normalized to untreated control. (N = 3, mean ± SEM, * p < 0.01, one-way ANOVA with Dunnett´s 
posttest comparing each treatment group to untreated group) 
Briefly, HEK293T cells were transfected with the promoter-reporter construct and 
individual Gal4 constructs from the library on 384 well plates (2.2.1). The next day, 
cells were stimulated for 24 h with 1 µM Dex, 100 ng/mL TNF-α, or both stimuli 
together and then subjected to measurement of reporter activity (2.6.7). The average of 
the luciferase activity from duplicate measurements was calculated. Fold changes of 
luciferase activity were calculated for each Gal4 fusion protein and stimulation 
condition over vehicle treatment. For each stimulation condition (Dex, TNF-α, Dex + 
TNF-α) and transcription factor species (human, mouse) the cut-off value for the fold 
change was determined graphically from a sorted rank. Above or underneath this value, 
the change in transcriptional activity was called significant. The sorted ranks of mouse 
and human transcription factors are depicted in Figure 8. The graph representing Dex-
stimulation ran differently than the TNF-α and Dex + TNF-α graphs, with lower 
elevations towards the end of the graph, where the maximum fold changes were 
represented. The TNF-α and Dex + TNF-α graphs, however, resembled each other thus 
indicating that the TNF-α effects were dominant in the co-stimulation experiment. 
These graphs showed also the greatest elevation at the ends and hence the greatest fold 
changes. For example, by using TNF-α, a maximum fold increase of 7.8 was detected. 
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Figure 8: The pro-atrophic stimulus TNF-α induced the greatest fold changes in transcriptional 
activity. The cell-based high-throughput screen was performed as described in Amelio, 2007 #28. Gal4 
constructs were transfected along with a Gal4 driven luciferase reporter into HEK293T cells as described 
in 2.2. Thereafter, cells were stimulated for 24 h with 1 µM Dex, 100 ng/mL TNF-α, or both stimuli 
together. Fold changes were plotted on a log2 scale against a sorted rank of fusion constructs from right to 
left. Fold changes are plotted over untreated control of relative luciferase activity from mouse and human 
transcription factors. 
In total, 6.9% of all tested transcription factors had an altered transcriptional activity, 
whereas more transcriptional regulators were changed towards a fold increase (4.7%) 
than fold decrease (2.2%) (Figure 9). Furthermore, more human transcriptional 
regulators (60%) than murine transcriptional regulators (40%) responded by a change in 
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luciferase expression under these settings in this cell line. The comparison of the 
different stimulation conditions revealed, that TNF-α treatment had the strongest effect 
on transcription factors, since 40% of all significantly altered transcription factors 
changed during this stimulation condition.  
 
Figure 9: From all tested Gal4 fusion proteins, 6.9% showed a fold change upon pro-atrophic 
stimulation as determined by a Cell-Based High-Throughput Screen in HEK293T cells. 
A) From 1450 tested Gal4 fusion proteins, 4.69 % responded via fold increase and 2.21% via a fold 
decrease towards pro-atrophic stimulation. 
B) From these 100 Factors, 40%, 34% and 26% showed a change of transcriptional activity upon TNF-α, 
TNF-α + Dex, or Dex stimulation. 
3.1.2 The Transcriptional Activity of Gal4-PSPC1 and Gal4-GAbpα was 
reproducibly altered 
Putative TNF-α targets from the screen were retested in HEK293T cells growing on 12-
well plates by using the mammalian one-hybrid assay. The cells were transfected with 
Gal4-Luc, Gal4 construct (Gal4-TF) and CMV-ß-gal (2.1.6), stimulated with 1 µM Dex, 
100 ng/mL TNF-α, or both stimuli together for 24 h (2.1.5) and harvested for 
determination of relative luciferase activity (2.6.7). The changes of relative luciferase 
activity were calculated as mentioned before and plotted upon normalization to 
untreated control settings. A selection of tested transcription factors after stimulation 
with TNF-α is shown in Figure 10. The changes of relative luciferase activity for the 
majority of the TNF-α targets from the screen (USA) could not be reproduced on 12-
well plate format (GER) (Figure 10). In addition, some of the screen targets had a 
relatively big standard deviation. 
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Figure 10: Relative luciferase activity of Gal4-PSPC1 and Gal4-GAbpα were reproducibly altered 
in TNF-α treated HEK293T cells as compared to putative Gal4-TF TNFα targets. For the manual 
setup, HEK293T cells were transfected with Gal4-Luc, pCMV-ß-gal, and Gal4-TFx and stimulated for 24 
h with 100 ng/mL TNF-α. Thereafter, the luciferase activity was determined. Relative luciferase activity 
was plotted as fold change over untreated control by comparing screen settings (USA) on 384-well plates 
to a manual set-up on 12 well plates (GER). (N=2 (USA), N=3 (GER), mean ± stddev) 
Based on these results, two candidates were chosen which showed a reproducible fold 
change in the screen settings and on 12-well plate format: Gal4-GAbpα showed a ~ 
70%-fold decrease and Gal4-PSPC1 a 2.9-fold increase upon stimulation with TNF-α 
(Figure 11). “GA binding protein alpha” (GAbpα) is a transcriptional regulator 
identified from the mouse library, while PSPC1 is a factor from the human screen and 
stands for “Paraspeckle component 1”. 
In order to assess whether the fold change upon TNF-α stimulation was due to a change 
in protein expression, the protein levels of Gal4 fusion proteins were analyzed. First, 
HEK293T cells were transfected under assay settings (2.1.6) and treated with 100 
ng/mL TNF-α, or left untreated for 24 h. Following this, overexpression of Gal4 fusion 
proteins was analyzed via western-blotting using the mouse Gal4-DBD antibody (2.6.3). 
Valosin containing protein (VCP) was used as loading control. 
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Figure 11: Alteration of relative luciferase activity of Gal4-PSPC1 or Gal4-GAbpα upon pro-
atrophic stimulation. For the mammalian one-hybrid assay in HEK293T cells, cells were transfected 
with Gal4-Luc, pCMV-ß-gal, and Gal4, Gal4-PSPC1 or Gal4-GAbpα, respectively. Subsequent 
stimulation was carried out for 24 h with 100 ng/mL TNF-α, 1 µM Dex, or both stimuli together. 
Thereafter, relative luciferase activity was determined and normalized to untreated (vehicle) control. (N = 
3-6, one (Gal4) and two independent experiments (Gal4-PSPC1, Gal4-GAbpα), mean ± SEM, * p < 0.01, 
one-way ANOVA with Dunnett´s posttest comparing each treatment group to control group) 
The protein levels of Gal4-PSPC1 and Gal4-GAbpα were slightly up-regulated upon 
TNF-α treatment of HEK293T cells (Figure 12). Most importantly, no decreased protein 
levels of Gal4-GAbpα or increased levels of Gal4-PSPC1 were detected upon TNF-α 
treatment, thus, indicating that changes in luciferase activity were indeed due to a 
change in transcriptional activity and not because of a change in protein expression. 
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Figure 12: The activity of Gal4-GAbpα and Gal4-PSPC1 was not regulated via protein expression 
in TNF-α stimulated HEK293T cells. For western-blot analysis of overexpressed proteins in HEK293T 
cells, cells were transfected with indicated Gal4 fusion proteins and stimulated for 24 h with 100 ng/mL 
TNF-α or left untreated. Following this, whole cells extracts were prepared and subjected to western-
blotting with the mouse antibody Gal4-DBD (2.6.3). Western-blot with VCP was used as loading control. 
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3.1.3 Validation of TNF-α targets in C2C12 cells 
Since the aim of this study was to investigate the dysregulated transcriptional activity of 
novel transcriptional regulators under pro-inflammatory settings in muscle, C2C12 cells 
were employed in this study. These cells had previously been established as an in vitro 
muscle cell culture model (Yaffe & Saxel 1977). C2C12 cells can easily be propagated 
as muscle precursor cells, named myoblasts. Upon serum deprivation and after reaching 
> 95% confluency, these cells start to fuse into multinucleated myotubes which form 
within 2-4 days of the differentiation process (Figure 13). In parallel, the expression of 
the muscle specific protein myosin is increased (Figure 14). 
 
Figure 13: C2C12 LP myoblasts fuse into multinucleated C2C12 myotubes within the course of 
differentiation. Light microscopy images of C2C12 myoblasts which were allowed to reach > 95% 
confluency and thereafter induced to differentiate by switching from growth medium (GM) to 
differentiation medium (DM).  
Initially, C2C12 cells were tested for their applicability as an in vitro model for Dex or 
TNF-α mediated muscle atrophy. Hence, C2C12 myotubes were stimulated for 24 h 
with 100 ng/mL TNF-α, 1 µM Dex or both stimuli together (2.1.5). Whole cell extracts 
were prepared and assessed for expression of myosin (2.6.6). This muscle-specific 
protein was found to be significantly decreased upon pro-atrophic stimulation with 
TNF-α and Interferon gamma (IFN-γ) (Figure 14) (Acharyya et al. 2004). However, no 
change in protein levels could be detected for Dex treatment or the TNF-α + Dex co-
treated C2C12 myotubes. This suggests, that stimulation of C2C12 cells with TNF-α 
does indeed provide a suitable in vitro model for TNF-α mediated muscle atrophy.  
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Figure 14: Myosin protein levels increased along with the differentiation process in C2C12 cells and 
decreased upon stimulation of C2C12 myotubes with TNF-α.  
A) Western-blot analysis of endogenous myosin protein levels in differentiating C2C12 myocytes. C2C12 
cells were allowed to differentiate over 5 days. Whole cell extracts were prepared from C2C12 myoblasts 
(day 0) and on each day of the differentiation process. Thereafter, myosin protein levels were analyzed by 
western-blot (2.6.3). 
B) Western-blot analysis of endogenous myosin protein levels in C2C12 myocytes C2C12 myotubes 
were stimulated overnight with 100 ng/ mL TNF-α, 1 µM Dex or both stimuli at once in DM. Thereafter 
myosin protein levels were analyzed by western-blot (2.6.3) and VCP protein levels were detected as 
loading control.  
The identified screen targets - PSPC1 and GAbpα - were tested for an alteration of 
transcriptional activity in C2C12 cells by the mammalian one-hybrid assay. For this 
purpose, C2C12 cells were transfected with Gal4-Luc and Gal4-DBD (Gal4) or Gal4-
TF (2.1.6) and treated with 25 ng/mL TNF-α for 24 h (2.1.5).  
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Figure 15: The relative luciferase activity of Gal4-GAbpα decreased upon stimulation with TNF-α 
in C2C12 cells. C2C12 cells were transfected with Gal4-Luc, CMV-ß-gal, and Gal4 or Gal4-GAbpα, 
respectively. Following this, cells were stimulated for 24 h with 25 ng/mL TNF-α and subjected to 
determination of relative luciferase activity. Relative luciferase activity was normalized to untreated 
control (N = 3, mean ± SEM, p = 0.025). 
The transcriptional activity of Gal4-PSCP1 in C2C12 cells – as determined by the 
ability to induce reporter gene expression under basal conditions – were not higher than 
two-fold above background and hence almost not detectable (data not shown). Under 
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the same conditions, however, the basal transcriptional activity of Gal4-GAbpα was 
significantly detectable above background. Stimulation with TNF-α caused a decrease 
of relative luciferase activity (Figure 15). Again, the expression levels of Gal4 fusion 
proteins were analyzed via western-blot (2.6.3). Upon transfection of C2C12 cells under 
assay conditions, cells were stimulated for 24 h with 10 or 100 ng/mL TNF-α, or left 
untreated (2.1.5). As control, overexpression levels of Gal4-PSPC1 were also analyzed 
in C2C12 cells. Despite the fact, that no transcriptional activity of Gal4-PSPC1 was 
detectable in C2C12 cells, the PSPC1 protein was identified at protein levels (Figure 
16). The protein levels of Gal4-GAbpα were not altered upon stimulation with TNF-α. 
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Figure 16: Western-blot analysis of overexpressed Gal4 fusion protein levels in C2C12 cells. Cells 
were transfected with no DNA at all (C), pGal4-PSPC1 or pGal4-GAbpα. Then, cells were stimulated 
with 10 or 100 ng/ mL TNF-α, or left untreated. Whole cell extracts were prepared and analyzed for 
protein overexpression by western-blot with the anti-Gal4 antibody or anti-VCP as loading control 
(2.6.6). (E: empty lane; M: Marker (protein ladder); C: Control) 
These data suggest that the transcriptional activity of GAbpα is decreased in a pro-
inflammatory condition. Furthermore, GAbpα has been described to be crucial for 
several pathways which so far had not been addressed in the context of muscle atrophy. 
Following the initial discovery of this transcriptional regulator to activate transcription 
from viral promoters, the transcription of several mitochondrial respiration genes and 
sub-synaptic genes at the NMJ is likewise activated by GAbp (Rosmarin et al. 2004).  
 
3.1.4 TNF-α Does Not Regulate the Activity of GAbpα on the Expression 
Level in C2C12 Cells 
In solution GAbpα dimerizes with GAbpβ thereby forming the transcriptional active 
heterodimeric GAbp. A diminished expression of GAbpβ upon TNF-α signalling might 
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also cause a decreased transcriptional activity of GAbpα, since GAbpβ mediates the 
protein-protein interactions to the basal transcription machinery. Therefore, the 
expression of GAbpβ was analyzed via qRT-PCR. C2C12 myoblasts were allowed to 
differentiate into C2C12 myotubes and then stimulated overnight with 5 ng/mL or 25 
ng/mL TNF-α. These cells were then harvested, targeted to RNA extraction (2.5.1), 
cDNA synthesis (2.4.9) and qRT-PCR analysis (2.4.2.2). GAbpβ mRNA levels were not 
changed upon TNF-α treatment of C2C12 cells, while transcript levels of GAbpα were 
slightly downregulated upon treatment with TNF-α (Figure 17).  
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Figure 17: Analysis of relative mRNA levels and protein levels GAbp in C2C12 myotubes. 
A) Relative quantification of mRNA levels of GAbpα and GAbpβ in C2C12 cells by qRT-PCR analysis. 
C2C12 myoblasts were allowed to differentiate for ~ 4 days into C2C12 myotubes. Fully differentiated 
myotubes were then stimulated overnight with 5 ng/mL or 25 ng/mL TNF-α. RNA was extracted, cDNA 
synthesis carried out and the mRNA levels of GAbpα and GAbpβ detected by qRT-PCR (N = 1, mean ± 
STDEV, STDEV represents variation from PCR replicates).  
B) Western-Blot of endogenous proteins in TNF-α stimulated C2C12 myotubes. Myotubes were 
stimulation overnight with 5 or 25 ng/mL TNF-α and subjected to preparation of native protein extracts.  
Along with this experiment, the endogenous protein levels of GAbpα and GAbpβ were 
also analyzed in C2C12 myotubes. For this purpose, cells were seeded on 6-well plates, 
and allowed to differentiate into myotubes. Following this, cells were stimulated 
overnight with 5 or 25 ng/mL TNF-α and subjected to preparation of native protein cell 
extracts. These extracts were then analyzed by western-blot. While the protein levels of 
myosin again decreased upon TNF-α treatment, the levels of GAbpα and GAbpβ 
remained unaltered under these conditions (Figure 17). In conclusion, TNF-α signalling 
in C2C12 does not regulate the activity of GAbp on the expression level.  
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Overall, Gal4-GAbpα was identified as a novel transcriptional regulator with 
dysregulated activity in TNF-α treated HEK293T and C2C12 cells. 
3.2 Knock-Down of GAbpα in C2C12 Cells by Lentiviral 
Delivery of a GAbpα-specific miRNA 
The physiological importance of GAbpα in muscle cells was addressed by a transient 
knock-down of GAbpα in C2C12 cells. As described previously, the whole-body 
knock-out of GAbpα and conditional knock-down in muscle-tissue have already 
underlined the physiological importance of GAbpα in the context of the NMJ (de 
Kerchove D'Exaerde et al. 2002; Ristevski et al. 2004). However, transient loss-of-
function studies of GAbpα in muscle tissue have not been examined so far. The 
advantage of transient loss-of-function studies is that they mimic acute effects, which 
are of interest especially in the context of a chronic inflammation process. In this study, 
the loss-of-function of GAbpα by lentiviral mediated delivery of an RNAi against 
GAbpα was addressed. 
3.2.1 GAbpα Was Efficiently Knocked-Down by a miRNA  
The effectors of RNAi mediated knock-down can either be small hairpin RNAs 
(shRNA) or micro-RNA (miRNA)-based shRNA. While shRNAs are transcribed from 
constitutive active pol III promoters (U6), miRNAs are transcribed from pol II 
promoters, which may be used also in a tissue-specific manner (Wiznerowicz et al. 
2006). With the aim to knock-down GAbpα in C2C12 cells in vitro and eventually later 
on in muscle tissue, miRNAs were chosen as RNAi molecule. Since alternative splicing 
variants of GAbpα, which vary within the 5’ untranslated region (UTR), have 
previously been described, miRNAs targeting the 3’UTR were designed (O'Leary et al. 
2005).  
For miRNA design, two different splice variants of GAbpα were used, which vary in the 
length of the 3’UTR (2.7.1). The GAbpα sequence with the Pubmed accession number 
NM008065 carries a ~ 1 kb longer 3’UTR than the GAbpα sequence with the accession 
number BC013562. Based on these sequences, the miRNA1256 was predicted to have 
the highest knock-down efficiency on GAbpα with the short 3`UTR, while miRNA4216 
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and miRNA4682 were predicted to have the highest knock-down efficiency on GAbpα 
with the accession number NM 008065. All three designed RNAi molecules were 
cloned into a miRNA expression vector, resulting in pcDNA6.2-GW/EmGFP-
miRNA1256, -miRNA4216 and –miRNA4682 (2.7.2). 
The knock-down efficiency of these designed RNAi molecules was tested thereafter by 
employing the “GeneEraser™ Luciferase Suppression-Test System”. For this purpose, a 
vector carrying the targeted gene sequence of GAbpα had to be cloned into the 3´UTR 
of the luciferase gene (pTarget vector). Upon transfection into HEK293 cells, this 
vector expresses a luciferase-target gene mRNA reporter construct. This consisted of 
the coding region for the luciferase reporter enzyme, a translational stop codon, the 
target gene, and the 3`UTR of the luciferase. Co-expression of functional RNAi 
molecules causes degradation of the luciferase-target gene mRNA. Due to the length of 
the 3’UTR of GAbpα (~ 3 kb), two different pTarget vectors containing the miRNA 
target sites were cloned (2.7.3). The plasmid pTarget-GAbpα-ORF contained the 
complete open reading frame (ORF) (1106 bp) of GAbpα and a small portion of the 
3’UTR (616 bp) and was targeted by miRNA1256. The ramaining part of the 3’UTR 
(2347 bp) was cloned into a second pTarget vector, pTarget-GAbpα-3’UTR, and 
targeted by miRNA4216 and -4682. 
Following cloning, these plasmids were analysed in the pTarget system in HEK293 
cells (2.7.4). The miRNA4216 and -4682 did not decrease reporter activity of the 
pTarget-GAbpα-3’UTR as compared to control miRNA, an unspecific miRNA 
sequence (miRNA NC), which served as negative control (data not shown). However, 
overexpression of miRNA1256 resulted in a dose-dependent decrease of reporter 
activity from the pTarget-Gabpα-ORF vector compared to control miRNA in HEK293 
cells (Figure 18). Since a minimal amount of RNAi tested (1 ng miRNA) yielded still a 
knock-down effect of > 70%, this miRNA was found to be very effective. Thus, 
miRNA1256 targeted efficiently degradation of the GAbpα target gene. 
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Figure 18: The miRNA1256 (miRNA GAbpα) was very efficient for knock-down of a luciferase-
target gene mRNA reporter construct (pTarget-GAbpα-ORF) in HEK293 cells (2.7.4). Cells were 
transfected with 100 ng pTarget-GAbpα-ORF and indicated amounts of pCDNA6.2-GW/EmGFP-
miRNA 1256 or – miRNA NC. Relative luciferase activity was determined as described in M X and 
normalized to the relative luciferase activity of miRNA NC. (N = 9, three independent experiments, mean 
± SEM, * p< 0.0001, t test for comparison between miRNA GAbpα versus miRNA NC for each group 
separately) 
Next, the knock-down efficiency of the miRNA1256 was tested on GAbpα protein 
levels by overexpression of the miRNA1256 vector along with an expression vector for 
GAbpα (2.7.5). For this purpose, an overexpression vector for GAbpα had to be cloned. 
The coding sequence of GAbpα was obtained through restriction digest of the insert 
GAbpα-ORF from the pTarget-GAbpα-ORF vector by using NotI (2.4.3). Along with 
this, the pcDNA3.1(-) vector was subjected to digestion with NotI and then 
dephosphorylated (2.4.10). Both, insert and vector, were then ligated (2.4.7). 
Completion of the cloning procedure resulted in an expression vector for GAbpα 
(pcDNA3.1(-)GAbpα) (2.4.12).  
HEK293T cells were transfected with 2 µg of pcDNA3.1-GAbpα (2.1.4.1). 
Concomitantly, cells were transfected with 0, 0.5, 1, 2 or 4 µg pcDNA6.2-GW/EmGFP-
miRNA 1256. In a further transfection reaction, co-transfection with 4 µg pcDNA6.2-
GW/EmGFP-miRNA NC served as negative control. Thereafter, whole cell extracts 
were prepared and analyzed for overexpression of GAbpα by western-blot (2.6.6). The 
loading control VCP confirmed uniform protein loading in each sample (Figure 19). 
The knock-down of overexpressed GAbpα was efficiently detected already at the 
minimal amount tested (0.5 µg miRNA1256). GAbpα protein levels were only slightly 
decreased by using the maximal amount of the unspecific miRNA (4 µg). 
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Figure 19: Overexpressed GAbpα protein levels in HEK293T cells were significantly decreased 
upon concomitant expression of the miRNA GAbpα. HEK293T cells were transfected with 2 µg 
pcDNA3.1-Gabpα in each experiment. In parallel, cells were transfected with 0 µg miRNA (first lane), 
0.5, 1, 2 or 4 µg miRNA GAbpα (second, third, fourth and fifth lane respectively) or 4 µg miRNA NC. 
Thereafter, whole cell extracts wer prepared and overexpressed GAbpα protein levels assessed by 
western-blot. As loading control, VCP protein levels were analyzed. 
Consequently, the miRNA 1256 (miRNA GAbpα) was used for knock-down of 
endogenous GAbpα in C2C12 cells via lentiviral delivery.  
3.2.2 Infection of C2C12 Cells with Lentivirus containing a miRNA GAbpα 
Expression Cassette 
The advantage of lentiviral gene delivery is a stable transduction even of non dividing 
and fully differentiated cells as well as long-term transgene expression, since the gene 
of interest is integrated into the host genome (Naldini 1998; Tiscornia et al. 2006). 
Delivery of the miRNA by transfection was not suitable in this setting due to the 
relatively low transfection efficiency of C2C12 cells. Therefore, a lentivirus vector 
system was chosen for the delivery of the miRNA into proliferating C2C12 myoblasts 
and differentiated C2C12 myotubes.  
Based on the design and cloning of the miRNA by using the “Block-iT Pol II miR 
RNAi Expression Vector Kits” from Invitrogen, the “Lentiviral Pol II miR RNAi 
Expression System” was employed in this study for generation of the lentiviral 
destination vector (2.7.6). This vector contained the miRNA GAbpα expression 
cassette. Next, this destination vector was utilized for generation of lentivirus in 293FT 
cells (2.8.1). Co-cistronic expression of GFP from the pLenti6-GAbpα and -NC allowed 
for evaluation of lentivirus production in the packaging cell line 293FT via microscopic 
analysis. Over 90% of lentivirus producing cells showed GFP expression indicating a 
successful transfection of 293FT cells and lentivirus production with the pLenti6-
GAbpα, -NC and helper plasmids (Figure 20).  
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Figure 20: Production of lentivirus in HEK293FT cells. HEK293FT cells were transfected with 
helper plasmids and pLenti6-Gabpα as described in 2.8.1. The next day, co-cistronic GFP 
expression was analyzed by microscopic analysis. A) Phase Contrast B) GFP  
The lentivirus containing supernatant was harvested and C2C12 cells transduced with 
virus using a dilution range of 1x10-2 to 1x10-6 (2.8.4). However, no GFP expression 
was detected in C2C12 cells by microscopic analysis (data not shown). Next, various 
variations from the protocol were tested to obtain efficiently transduced C2C12 cells. 
These were for instance production of lentivirus from more 293FT cells, harvest of 
virus containing supernatant on different days, transduction of C2C12 cells with a 
higher virus titer. Yet, no efficiently transduced C2C12 cells were detectable upon 
transduction with such prepared virus. 
Based on these results, an alternative protocol for producing lentivirus was tested 
(2.8.2). This time, HEK293T cells were employed as packaging cell line and transfected 
for this purpose on 2x15cm dishes per miRNA (GAbpα and NC). Virus harvest was 
performed on day 3 after transfection. This virus was then diluted 1:2 and 1:5 for 
transduction of C2C12 cells and HEK293T cells, respectively. Transduction was 
performed during passaging by using polybrene (2.8.4). While ~ 100% of transduced 
HEK293T cells showed GFP expression, ~ 5% of transduced C2C12 cells were GFP 
positive. With the aim to concentrate lentivirus, an ultracentrifugation step was 
performed directly after the harvest of virus from the producer cell line (2.8.3). Such 
concentrated lentivirus was titered in C2C12 cells by using serial dilutions of the 
lentiviral stock which ranged from 1.5x10-4 to 1.5x10-8 (2.8.5). Cells were subjected to 
Blasticidin selection for the course of 10 days. Thereafter, surviving colonies were 
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detected by crystal violet staining, counted and in consideration of the virus titer 
expressed as transforming units (TU) per mL. 
 
Figure 21: Determination of virus titer via crystal violet staining of transduced and blasticidin 
selected C2C12 cells (2.8.5). C2C12 cells were transduced with concentrated lentivirus (stock) that 
contained as transgene an expression cassette for the miRNA NC (A) or Gabpα (B). In parallel, serial 
dilutions of the lentiviral stock were prepared which ranged from 1.5x102 to 1.5x10-7 and cells were also 
transduced with diluted lentivirus. Thereafter, cells were subjected to blasticidin selection for 10 days. 
Following this, surviving colonies were detected by crystal violet staining.  
The titer of the lentivirus containing miRNA NC (Figure 21 A) and miRNA GAbpα 
(Figure 21 B) was determined to 3.3x108 TU/mL and 2.6x107 TU/mL, respectively. 
Following this, C2C12 cells were transduced using an MOI of 1 and 5 and such 
subjected to lysis for protein analysis (2.6.6). Protein samples were analyzed via 
western-blot for knock-down of GAbpα, however, no change in protein levels was 
detected in miRNA GAbpα versus miRNA NC cells (data not shown). Thus, the 
lentivirus generated in this study was obviously inefficient for transient transduction of 
C2C12 cells and transient knock-down of GAbpα protein levels. 
Finally, stable transduced C2C12 cells were prepared (2.8.6). By using blasticidin 
selection, untransduced cells were eliminated and efficiently transduced cells enriched. 
The latter was allowed to differentiate and tested on protein and mRNA level for knock-
down of GAbpα (Figure 22). The relative mRNA levels of GAbpα in miRNA NC 
containing C2C12 cell clones were slightly increased compared to the untreated control 
(C). In contrast, the transcript levels of GAbpα in miRNA GAbpα containing C2C12 
cell clones remained unchanged (see for instance clone 1 and 5) or were not 
significantly decreased (clone 4 and 6). In addition, GAbpα protein expression was also 
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assessed by western-blot of stable transduced C2C12 cells (2.6.6). Samples 2 and 3 of 
miRNA NC containing C2C12 cells showed a protein decrease compared to sample 1 
thus indicating unspecific effects. A similar observation was made with samples derived 
from miRNA GAbpα C2C12 cells. Here, samples 2 and 3 seemed to contain less 
GAbpα than sample 1. Similar results were obtained when analyzing samples 4-6 from 
miRNA NC or GAbpα (data not shown). To conclude, no miRNA GAbpα specific 
knock-down of GAbpα was detected in stable transduced C2C12 cells as compared to 
unspecific control (miRNA NC). 
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Figure 22: Stable transduced C2C12 myotubes showed no significant decreased of relative GAbpα 
mRNA or protein levels. 
A) C2C12 myotubes stably expressing miRNA expression cassettes, Gabpα or NC, were taken for mRNA 
analysis. Normalization was carried out over untransduced C2C12 myotubes (C). (N = 1, mean ± 
STDEV, STDEV represents variation from PCR replicates)  
B) Stable transduced C2C12 cells were prepared as described in the 2.8.6. These cells were then 
differentiated into C2C12 myotubes. Following this, native cell extracts were prepared and protein levels 
analyzed by western-blot. Shown are three representative cell clones per miRNA. 
While establishing an RNAi-mediated knock-down system for GAbpα in C2C12 cells, 
two muscle-specific knock-out studies of GAbpα were published (Jaworski et al. 2007; 
O'Leary et al. 2007). These studies further supported the importance of this 
transcriptional regulator for the functional integrity of the NMJ. However, the molecular 
mechanisms underlying the transcriptional regulation of sub-synaptic target genes in 
muscle cells had not been addressed in these studies. Since the transcriptional regulation 
of GAbp was of novel interest, the elucidation of this mechanism was further addressed 
in this study. 
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3.3 The Transcriptional Active GAbp Heterodimer Dissociates 
in TNF-α Stimulated C2C12 Cells 
 
3.3.1 TNF-α Treatment of C2C12 Cells Causes the Dissociation of the 
Heterodimeric GAbp 
As shown before in this study, the transcriptional activity of overexpressed GAbpα 
decreased upon TNF-α stimulation of HEK293T and C2C12 cells in a mammalian one-
hybrid assay. The altered transcriptional activity of GAbpα was not regulated by 
transcription as shown by determination of endogenous mRNA and protein levels of 
GAbpα and GAbpβ in C2C12 cells (Figure 17). Since the individual DNA-binding 
activity of GAbpα is not detectable by the mammalian one-hybrid assay - DNA-binding 
occurs in this assay exclusively via the Gal4 DNA-binding domain - a change in the 
DNA binding of GAbpα, which might also cause an alteration of transcriptional 
activity, could be ruled out. As another possibility for a diminished transcriptional 
activity, the dissociation of the GAbp complex was addressed. Since the transcriptional 
activation domain and DNA binding domain of GAbp are separated on two different 
proteins, GAbpα and GAbpβ, dissociation was predicted to lower the activity. A 
suitable tool for studying protein-protein interactions in cell culture is the mammalian 
two-hybrid assay. For this purpose, two fusion proteins are expressed, each containing a 
different tag. While one protein carries a DNA binding domain, for example Gal4, the 
other contains a transcriptional activation domain, for example Vp16. Upon co-
transfection with a Gal4 driven luciferase reporter into a mammalian cell line, the 
interaction of these proteins is represented by an increased luciferase expression. 
Noteworthy, an increased luciferase activity stands for the close proximity of both 
proteins and not a transcriptional activity of the overexpressed proteins like it is 
detectable by the mammalian one-hybrid assay. Consequently, a diminished luciferase 
expression suggests that a dissociation of both proteins has occurred. Usually, the tags 
alone, Gal4 and Vp16 are used as negative control. 
Since GAbpα was already available as fusion protein with the Gal4 DNA binding 
domain, a fusion protein of GAbpβ with Vp16 was cloned. The coding region of GAbpβ 
was amplified from the plasmid pcDNA3.1(-)GAbpβ by using the primer pair GAbpβ-
Vp16-for and GAbpβ-Vp16-rev via PCR. The cloning procedure for pcDNA3.1(-
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)Gabpβ is described in 3.4.1. Upon restriction digest of both vector and insert with KpnI 
and NheI, the PCR product was then cloned into the pCMX-Vp16 vector. This Vp16-
GAbpβ expression protein contained the Vp16 domain at the N-terminus. Following 
this, a mammalian two-hybrid assay was performed in C2C12 cells (2.1.6). As negative 
controls, Gal4 and Vp16 constructs were transfected while the interaction of GAbpβ and 
GAbpα was analyzed by transfection of Gal4-GAbpα and Vp16-GAbpβ (2.1.4.2). 
Transfected cells were stimulated for 48 h with 25 ng/mL TNF-α, or left untreated 
(2.1.5), and finally assayed for relative luciferase activity (2.6.5) (Figure 23). 
0,00
0,20
0,40
0,60
0,80
1,00
1,20
1,40
R
el
at
iv
e 
Lu
ci
fe
ra
se
A
ct
iv
ity
Gal4 Gabpα ++- -
Vp16 Gabpß ++- -
Gal4 + + - -
Vp16 ++ - -
Control
TNF-α
*
 
Figure 23: Gal4-GAbpα and Vp16-GAbpβ dissociate upon TNF-α treatment of C2C12 cells. For the 
mammalian two-hybrid assay, C2C12 cells were transfected with Gal4-Luc and CMV-ß-gal as well as 
indicated constructs and stimulated for 48 h with 25 ng/mL TNF-α or left untreated. Following this, 
relative luciferase activity was determined and normalized to untreated (control) co-expression of Gal4-
GAbpα and Vp16-GAbpβ (N = 9, 3 independent experiments, mean ± SEM, * p < 0.001, t test. Usually, 
this transfection and stimulation experimental design requires a multifactorial ANOVA analysis. 
However, for simplicity a t test was performed. In addition, since the TNF-α effect in each transfection 
group individually was of interest, this statistical analysis method was found to be more adequate here). 
No luciferase activity was detectable in the negative control settings. Thus, no 
interaction occurred between Gal4 with Vp16, Gal4 with Vp16-GAbpβ or Gal4-GAbpα 
with Vp16. Co-expression of Gal4-GAbpα with Vp16-GAbpβ induced, however, 
clearly the expression of the luciferase reporter via the Gal4 promoter, thus, underlying 
the specific protein-protein interaction between these proteins. Stimulation with TNF-α 
resulted in a significant reduction of reporter gene expression (p < 0.001). This 
decreased protein-protein interaction indicates a dissociation of the transcriptional 
active heterodimer due to the pro-inflammatory cytokine TNF-α. 
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In order to assess whether TNF-α mediated dissociation occurs in C2C12 cells on 
endogenous protein levels as well, a co-immunoprecipitation was performed (2.6.4). 
C2C12 myotubes were stimulated for 30 min with 25 ng/mL TNF-α (2.1.5) and then 
targeted to co-immunoprecipitation by using a polyclonal GAbpβ antibody. 
Immunoblotting with a polyclonal murine GAbpβ antibody confirmed that equal 
amounts of GAbpβ were pulled down in TNF-α treated and control C2C12 cells (2.6.3). 
Concomitantly, less GAbpα was detected in the eluate upon TNF-α treatment. This 
strengthens the finding from the mammalian two-hybrid assay and indicates the 
dissociation of endogenous proteins in response to TNF-α. 
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Figure 24: The heterodimeric GAbp complex dissociates upon TNF-α stimulation of C2C12 
myotubes. Co-immunoprecipitation of GAbpβ and GAbpα was performed from extracts of C2C12 
myotubes. Cells were allowed to differentiate, stimulated for 30 min with 25 ng/mL TNF-α, extracted and 
subsequently subjected to immunoprecipitation with an antibody against GAbpβ. The presence of GAbpα 
and GAbpβ was analyzed by western-blot in the input and eluate fractions (IP). 
 
3.3.2 The Minimal Interaction Domains of GAbpα and GAbpβ are 
Sufficient for TNF-α Mediated Dissociation of the Complex 
The dissociation of the GAbp complex might be caused by post-translational 
modifications (e.g. phosphorylations) or changes in protein-protein interactions with 
other transcriptional regulators or the basal transcriptional proteins. As mentioned 
earlier, several proteins have already been described to bind to GAbp, e.g. Sp1, HDAC, 
p300 (Rosmarin et al. 2004). Therefore, domain truncations of GAbpα and GAbpβ were 
cloned in order to identify those domains or post-translational modification sites 
required for TNF-α mediated dissociation via the mammalian two-hybrid assay. The 
domains crucial for the protein-protein interaction between GAbpα and GAbpβ were 
not modified to guarantee a functional protein-protein interaction in the mammalian 
two-hybrid assay. For this reason, all corresponding domain truncation constructs 
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carried the protein interaction domains, which are the C-terminal portion of GAbpα (aa 
325-349) and the N-terminal portion of GAbpβ (aa 1-169). 
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Figure 25: Illustration of cloned Gal4-GAbpα domain truncations (left) and overexpression analysis 
of corresponding fusion proteins in HEK293T cells (right). N-terminal domain deletions of GAbpα 
were cloned into the pGal4 vector. These Gal4-GAbpα fusion proteins were transfected into HEK293T 
cells for overexpression analysis. Whole cell extracts were performed and the fusion protein levels 
detected by western-blot using the Gal4 antibody. 
For cloning of Gal4-GAbpα domain truncation constructs, four different PCR reactions 
were performed to amplify various N-terminal domain truncations based on the Gal4-
GAbpα template (2.4.2.1). In all four PCR reactions the same reverse primer, GAbpα-
AscI-rev, was used. Deletion of the first 63 amino acids resulted in Gal4-GAbpα dOST, 
which was amplified by using dOST-PacI-for as forward primer. Next, deletion of the 
pointed domain (PNT) yielded dPNT by using the primer dPNT-PacI-for. Gal4-GAbpα 
dT280 was obtained by deleting the phosphorylation site T280 and dEts by removing 
the Ets DNA binding domain. In the latter case dEts-PacI-for was used as forward 
primer while dT280-PacI-for was used to generate Gal4-GAbpα dT280. Each of these 
PCR products was then subjected to restriction digest with PacI and AscI (2.4.3). 
Ligation of each these constructs into an identically digested pGal4 vector resulted in 
Gal4 fusion proteins (2.4.7) (Figure 25). Confirmed plasmids were used for 
overexpression analysis in HEK293T cells via western-blot by using a Gal4 antibody 
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(2.6.6). The proteins migrated at expected size, thus, indicating a correct expression of 
the truncated Gal4-GAbpα proteins (Figure 25).  
Next, Gal4-GAbpα domain truncation constructs were analyzed in a mammalian two-
hybrid assay (2.1.6). C2C12 cells were transfected with pGal4-Luc, pCMV-ß-gal and 
pVp16-GAbpβ on each well. Along with this, six different Gal4 fusion proteins, Gal4, 
Gal4-GAbpα, dOST, dPNT, dT280, or dEts, were transfected on corresponding wells. 
Cells were stimulated with 25 ng/mL TNF-α and assayed thereafter for relative 
luciferase activity (2.6.7). 
In this study, the Gal4-GAbpα fusion protein contained an N-terminal deletion of ~ 100 
aa of GAbpα (Pubmed accession number BC013562). At the time-point of the screen, 
this part of the N-terminus of GAbpα (aa 1-63 of the BC013562) was not associated 
with any function. Later, structural characterization of GAbpα revealed that this domain 
folds into stable folded structure and was named OST domain (Kang et al. 2008). Upon 
deletion of the OST domain, PNT domain or T280 site, a decrease of relative luciferase 
activity was detected compared to the full length fusion protein. Hence, for these 
domain truncations of GAbpα the protein-protein interaction to Vp16-GAbpβ decreased 
~ 40% compared to the full length Gal4-GAbpα. TNF-α stimulation caused a significant 
decrease of relative luciferase activity in the positive control, the full length fusion 
protein Gal4-GAbpα, and three consecutive domain truncation constructs, dOST, dPNT, 
and dT280. This means, that with all tested domain truncations of Gal4-GAbpα, the 
protein-protein interaction to Vp16-GAbpβ decreased. No basal transcriptional activity 
and hence no decrease upon TNF-α treatment was detectable by using Gal4 alone or the 
Gal4-GAbpα dEts protein. This finding is according to previous studies claiming that 
the presence of the C-Terminus as well as the Ets domain were required for GAbpα 
binding to GAbpβ. Furthermore, these results indicate that the minimal GAbpβ-binding 
domain of Gal4-GAbpα protein is sufficient for the TNF-α mediated dissociation.  
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Figure 26: The protein-protein interaction between Vp16-GAbpβ and Gal4-GAbpα, dOST, dPNT, 
dT280 or dEts decreases upon stimulation with TNF-α. The mammalian two-hybrid assay was carried 
out in C2C12 cells, which were transfected with Gal4-Luc, CMV-ß-gal, and Vp16-GAbpβ as well as 
indicated Gal4 fusion proteins. Thereafter, cells were stimulated for 48 h with 25 ng/mL TNF-α or left 
untreated. Finally, relative luciferase activity was determined and normalized to untreated co-expression 
of Gal4-GAbpα and Vp16-GAbpβ. (N = 9, 3 independent experiments, mean ± SEM, * p < 0.001, t test, 
for details regarding the statistical analysis see Figure 23). 
Domain deletions of GAbpβ were then cloned into the pCMX-Vp16 for subsequent 
analysis via the mammalian two-hybrid assay. While the leucine zipper domain 
(LeuZip) is required for homodimerization of GAbpβ, the transcriptional activation 
domain (TAD) is crucial for activation of transcription. The minimal construct 
(dPhoSit) contained only the ankyrin repeats (ANK). In addition, this construct differed 
from dTAD by two missing putative phosporylation sites, which had been mapped to 
S170 and T180 (Figure 27). The DNA for the domain truncation constructs was 
amplified via PCR from the pVp16-GAbpβ vector by using the same forward primer, 
GAbpβ-Vp16-for, in all PCR reactions (2.4.2.1). Three different PCR reactions were 
carried out by using reverse primers GAbpβ-dLeuZip-rev, GAbpβ-dTAD-rev and 
GAbpβ-dPhoSit-rev in order to obtain the dLeuZip, dTAD and dPhoSit constructs, 
respectively. These inserts were then double digested with KpnI and NheI and each 
ligated into an identically digested pCMV-Vp16 vector (2.4.3, 2.4.7). The cloning 
procedure was finished as described in 2.4.12.  
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Figure 27: Scheme of Vp16-GAbpβ domain deletions and expression analysis. C-terminal domain 
deletions of GAbpβ were cloned into the pCMX-Vp16 vector. These Vp16-GAbpβ fusion proteins were 
analyzed via qRT-PCR upon transfection in C2C12 cells. Relative mRNA levels were normalized to the 
full length (Vp16-GAbpβ) protein. (mean + STDEV indicating pipetting errors) 
Due to the fact that the protein expression from the pCMX-Vp16 vector results in 
relatively low overexpressed protein levels (data not shown), a qRT-PCR analysis of 
transfected C2C12 cells was performed instead. For the qRT-PCR analysis, a probe 
targeting the Vp16 domain was employed to guarantee the proper detection of all 
constructs. C2C12 cells were transfected under assay conditions with the constructs for 
the full length fusion protein (Vp16-GAbpβ) or the domain truncations (dLeuZip, 
dTAD, dPhoSit) (2.1.6). Cells were harvested and targeted to RNA extraction (2.5.1), 
cDNA synthesis (2.4.9) and qRT-PCR analysis (2.4.2.2). The relative mRNA levels 
were normalized to the full length protein. The relative mRNA level of the dLeuZip 
protein was slightly decreased, while the relative mRNA levels of the dTAD and 
dPhoSit protein were increased (Figure 27).  
These Vp16-GAbpβ domain truncation proteins were then used in the mammalian two-
hybrid assay. C2C12 cells were transfected with pGal4-Luc, pCMV-ß-gal, and pGal4-
GAbpα on each well (2.1.6). Then, the different Vp16 constructs were tested by 
transfecting Vp16, Vp16-GAbpβ, dLeuZip, dTAD or dPhoSit. Following this, cells 
were stimulated for 48 h with 25 ng/mL TNF, or left untreated, and assessed for relative 
luciferase activity (2.1.5) (Figure 28). 
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Figure 28: The protein-protein interaction between Gal4-GAbpα and Vp16-GAbpβ, dLeuZip, 
dTAD, and dPhoSit decreases upon stimulation with TNF-α. The mammalian two-hybrid assay was 
performed in C2C12 cells as follows. Cells were transfected with Gal4-Luc, CMV-ß-gal, and Gal4-
GAbpα as well as indicated plasmids and stimulated for 48 h with 25 ng/mL TNF-α or left untreated. 
Finally, relative luciferase activity was determined and normalized to untreated co-expression of Gal4-
GAbpα and Vp16-GAbpβ. (N = 9, 3 independent experiments, mean ± SEM, * p < 0.05, t test, for details 
regarding the statistical analysis see Figure 23). 
Interestingly, deletion of the LeuZip domain caused an increase in relative luciferase 
expression hence indicating an increased protein-protein interaction compared to the 
full length fusion protein. However, deletion of both, the LeuZip and TAD domain in 
the dTAD protein resulted in a lower relative luciferase activity compared to the full 
length fusion protein. This was also true for the dPhoSit protein resulting from the 
simultaneous deletion of the LeuZip, TAD domain and phosphorylation sites, which 
gave rise to the dPhoSit protein. Despite the differing degree of protein-protein 
interaction of the tested domain deletion constructs, TNF-α treatment caused a 
significant decrease in relative luciferase activity upon overexpression of Gal4-GAbpα 
and Vp16-GAbpβ (p< 0.001), dLeuZip (p = 0.0038), dTAD (p = 0.0021), or dPhoSit (p 
= 0.0282). To conclude, the domain leading to TNF-α mediated dissociation of Gal4-
GAbpα from Vp16-GAbpβ is the minimal binding domain of Vp16-GAbpβ. 
Next, the minimal binding domains of Vp16-GAbpβ as well as Gal4-GAbpα were 
tested in the mammalian two hybrid assay for TNF-α mediated dissociation (2.1.6). 
C2C12 cells were transfected with Gal4-Luc, CMV-ß-gal, plus Vp16-GAbpβ dPhoSit 
and Gal4-GAbpα-dT280 and stimulated for 48 h with 25 ng/mL TNF-α (2.1.4.2, 2.1.5). 
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Thereafter, cells were lysed and targeted to determination of relative luciferase activity 
(Figure 29). 
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Figure 29: The minimal binding domains of Gal4-GAbpα (dT280) and Vp16-GAbpβ (dPhoSit) are 
sufficient for TNF-α mediated decrease of the protein-protein interaction. For the mammalian two-
hybrid assay, cells were transfected with Gal4-Luc, CMV-ß-gal as well as indicated plasmids and 
stimulated for 48 h with 25 ng/mL TNF-α or left untreated. Finally, relative luciferase activity was 
determined and normalized to untreated co-expression of Gal4-GAbpα and Vp16-GAbpβ. (N = 9, 3 
independent experiments, mean ± SEM, * p < 0.001, t test, for details regarding the statistical analysis see 
Figure 23). 
Again, only co-expression of Vp16-GAbpβ dPhoSit and Gal4-GAbpα dT280 caused a 
detectable luciferase activity compared to negative control settings indicating a strong 
protein-protein interaction (Figure 29). The relative luciferase activity diminished 
significantly (p < 0.001) after TNF-α treatment. This result suggests that the minimal 
binding domains of GAbpβ and GAbpα are also sufficient for dissociation of the GAbp 
complex under pro-inflammatory conditions. 
3.3.3 The Dissociation is Specific to TNF-α as Compared to Other Pro-
Inflammatory Stimuli 
Next, the specificity of this observation was addressed by testing other pro-
inflammatory stimuli for their ability to diminish the protein-protein interaction of 
GAbpα and GAbpβ in the mammalian two-hybrid assay. As mentioned earlier, along 
with TNF-α, the implication of the other pro-inflammatory cytokines like IFN-γ, IL-1β 
and IL-6 has been described in different models of muscle atrophy. In addition, 
RESULTS 
 
 
74 
lipopolysaccharides (LPS) were also analyzed in this study, since this bacterial 
endotoxin induces a strong immune response and activates tissue-residing macrophages 
in vivo. The latter can be mimicked in vitro by stimulating RAW cells, a mouse 
leukaemic monocyte macrophage cell line, with LPS and using such conditioned RAW 
medium (CM-RAW) for stimulation of other mammalian cells. Upon activation with 
LPS, RAW cells secrete pro-inflammatory cytokine, as for instance TNF-α. In this 
context, the conditioned RAW medium used in this study was analyzed by ELISA for 
presence of various cytokines. While IFN-γ and IL-1β were could not be detected, 2500 
pg/mL IL-6 and 1050 pg/mL TNF-α were detected thus indicating that these pro-
inflammatory are the predominant species in this medium (unpublished data). 
C2C12 cells were transfected with Gal4-Luc, CMV-ß-gal and the minimal domains of 
Vp16-GAbpβ (dPhoSit) and Gal4-GAbpα (dT280) (2.1.6). Thereafter, cells were 
stimulated for 48 h with 25 ng/mL TNF-α, 100 U/mL IFN-γ, 10 ng/mL IL-1β, 20 ng/mL 
IL-6, 100 ng/mL LPS, conditioned or control RAW medium or left untreated (2.1.5). 
The concentrations of these stimuli represent standard concentrations which are 
routinely used to mimic a chronic inflammation in cell culture. Finally, relative 
luciferase activity was determined (Figure 30). 
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Figure 30: The dissociation of Gal4-GAbpα dT280 from Vp16-GAbpβ dPhoSit is specific to TNF-α. 
Conditioned RAW medium shows a similar effect as TNF-α alone. C2C12 cells were transfected with 
Gal4-Luc and CMV-ß-gal as well as Gal4-GAbpα dT280 and Vp16-GAbpβ dPhoSit and stimulated for 
48 h with 25 ng/mL TNF-α, 100 U/mL IFN-γ, 20 ng/mL IL-6, 10 ng/mL IL-1β, or 100 ng/mL LPS or left 
untreated. In a parallel experiment, such transfected cells were stimulated for 48 h with control RAW 
medium or conditioned RAW medium (N = 9, 3 independent experiments, mean ± SEM, * p < 0.01, one-
way ANOVA with Dunnett´s posttest comparing each treated group to the corresponding control group). 
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In this mammalian two-hybrid assay, no decreased relative luciferase activity was 
detected in IFN-γ, IL-1β, IL-6, or LPS treated C2C12 cells. Interestingly, conditioned 
RAW medium, however, caused a significant decrease (p < 0.0001) similar to the TNF-
α effect. To conclude, the dissociation of the transcriptional active GAbp seems to be 
specific to TNF-α when compared to other pro-inflammatory cytokines. However, 
activated macrophages show the same effect. 
3.3.4 The TNF-α Mediated Dissociation of the GAbp complex is triggered 
by the Induction of Reactive Oxygen Species 
In the past, it was discovered that GAbp is subjected to redox regulation in 3T3 cells, 
thereby leading to changes GAbp-dependent gene expression (Martin et al. 1996). 
Furthermore, in a consecutive study, this effect was linked to GAbpα which carries four 
redox-sensitive cysteine residues within the Ets domain and the most C-terminal domain 
(Chinenov et al. 1998). Oxidation of these residues has been associated with a change in 
DNA binding and heterodimerization of both proteins (Chinenov et al. 1998). Since 
TNF-α is known to induce the production of reactive oxygen species (ROS), the redox 
regulation of GAbp heterodimerization was addressed in this study by the mammalian 
two-hybrid assay.  
ROS are molecules formed as natural byproducts during cellular respiration and are 
characterized by the presence of unpaired valence shell electrons giving rise to their 
high reactivity (e.g. hydrogen peroxide H2O2). Usually, ROS are not harmful to 
mammalian cells due to the antioxidative function of vitamins (e.g. ascorbic acid), 
enzymes (e.g. superoxide dismutase, catalase) or small molecules (glutathione). On the 
contrary, some crucial signalling pathways depend on ROS (apoptosis, transcriptional 
activation of host defence genes). In addition, they are produced by some components 
of the immune system for destruction of invading microbes. Accumulation of these 
compounds may, however, cause oxidative stress resulting in serious tissue damage. 
Moreover, ROS have been described to have a causal role in two different in vitro 
models of insulin resistance, a pathology being linked to the Metabolic Syndrome 
(Houstis et al. 2006). In the corresponding study, two different antioxidative compounds 
were used for proving the causal link. While Mn(III)tetrakis(4-benzoic acid)porphyrin 
Chloride (MnTBAP) is a cell-permeable superoxide dismutase (SOD) mimetic and 
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thereby protects cells from the damaging effects of H2O2, N-acetylcysteine (NAC) has 
similar effects by inducing the formation of glutathione in cells. 
Next, the question was addressed whether production of ROS was implicated in TNF-α 
mediated dissociation of GAbp. For this purpose, the mammalian two-hybrid assay was 
performed by using the full length fusion proteins of Gal4-GAbpα and Vp16-GAbpβ. 
C2C12 cells were transfected as described before (MX) and stimulated with 12.5 ng/mL 
TNF-α or 1 mM H2O2 for 48 h. Concomitantly, cells were targeted to increasing doses 
of MnTBAP (37.5 µM, 75 µM, and 150 µM) or NAC (1.25 mM, 2.5 mM, and 5 mM). 
Following this, the relative luciferase activity was determined (Figure 31). Interestingly, 
the relative luciferase activity decreased in H2O2 treated C2C12 cells suggesting a 
dissociation of Gal4-GAbpα and Vp16-GAbpβ under these conditions (Figure 31). The 
same was repeatedly true for TNF-α treated cells. Concomitant stimulation with H2O2 
and NAC rescued significantly the decrease in luciferase activity at 2.5 mM NAC (60 % 
rescue) and 5 mM NAC (80 % rescue). This could also be observed by concomitant 
treatment with MnTBAP and TNF-α (~ 52 % rescue) already at the mid-range 
concentration of 75 µM MnTBAP. A rescue of 80 % was achieved by using 5 mM 
NAC and TNF-α. 
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Figure 31: TNF-α or H2O2 mediated dissociation of GAbp in C2C12 cells is rescued by ROS 
inhibitors. C2C12 cells were transfected with pGal4-GAbpα, pVp16-GAbpβ, and pGal4-Luc. Thereafter, 
cells were stimulated with 25 ng/mL TNF-α or 1 mM H2O2. Concomitant treatment with ROS inhibitors 
was carried out by using 37.5 µM, 75 µM, 150 µM MnTBAP or 1.25 mM, 2.5 mM, or 5 mM NAC. 
Finally, relative luciferase activity was determined and normalized to untreated control. (N = 6, 2 
independent experiments, mean ± SEM, * p < 0.05, One-way ANOVA with Dunnett´s posttest comparing 
each group treated with a ROS inhibitor to the group with TNF-α stimulation alone). 
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Taken together, TNF-α stimulation of C2C12 cells leads to the dissociation of GAbpα 
and GAbpβ with the minimal binding domains being sufficient. This altered functional 
interaction was found to be specific for TNF-α as compared to other pro-inflammatory 
cytokines. Moreover, oxidative stress of C2C12 cells causes likewise a dissociation of 
the transcriptional active heterodimer. ROS inhibitors efficiently rescued the 
dissociation in both conditions, TNF-α stimulation and oxidative stress. 
3.4 TNF-α Inhibits Neuregulin Stimulated Expression of GAbp 
Target Genes in C2C12 Cells 
Next, the question was addressed, which implication the TNF-α mediated dissociation 
of GAbp has on the transcription regulation of GAbp target genes in C2C12 cells The 
heterodimeric transcription factor GAbp has been described to activate transcription of 
various target genes in different tissues. In muscle cells, GAbp plays a role in the 
development and organization of target genes crucial for the neuromuscular junction 
(NMJ). The AChRε is a prominent example of a gene regulated in such a way (Mejat et 
al. 2003). Stimulation of C2C12 cells with Neuregulin (NRG), which is a growth factor 
secreted from nerve cells and therefore commonly used for mimicking the events at the 
NMJ in vitro, is known to cause an increase in AChRε-transcription. The 
compartmentalized transcription of sub-synaptic target genes is accomplished by the 
presence of the N-Box within corresponding promoter sequences. This N-Box 
represents the consensus-motif for binding of GAbp through its DNA binding 
component GAbpα. In this study, the impact of TNF-α mediated dissociation of GAbpα 
and GAbpβ was analyzed on putative target genes by using an artificial 3xNBox 
promoter and the natural AChRε promoter. 
3.4.1 TNF-α inhibits the Activation of a 3xNBox Promoter by NRG 
For the 3xNBox promoter study, C2C12 cells were transfected with the pCMV-ß-gal, 
p3xNBox promoter or control vector (pTAL-Luc) and stimulated for 48 h with 5 nM 
Neuregulin (NRG), 25 ng/mL TNF-α, NRG and TNF-α together, or left untreated 
(2.1.7, 2.1.5). Then, relative luciferase activity was determined and normalized to NRG 
stimulated cells (Figure 32).  
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Figure 32: TNF-α inhibits NRG mediated induction of 3xNBox promoter activity. C2C12 cells were 
transfected with pCMV-ß-gal and pTAL-Luc or p3xNBox-Luc and stimulated for 48 h with 5 nM 
Neuregulin (NRG), 25 ng/mL TNF-α, NRG + TNF-α, or left untreated. Then, relative luciferase activity 
was determined and normalized to NRG stimulated cells (N = 9, 3 independent experiments, mean ± 
SEM, * p < 0.01, two-way ANOVA with Bonferroni posttests comparing vehicle versus NRG in the 
absence or presence of the TNF-α). 
The promoter activity of the control vector (pTAL-Luc), which contains the backbone 
DNA sequence without the artificial 3xNBox consensus motif, did not change under 
these conditions. NRG stimulation caused an increase in 3xNBox-promoter activity of ~ 
45%, while TNF-α stimulation treatment led to no significant alteration of promoter 
activity. However, NRG stimulation in the presence of TNF-α significantly inhibited the 
promoter activity. In this promoter assay, the interaction between NRG and TNF-α 
treatment was not significant (Interaction p = 0.0863). In summary, a trend towards an 
inhibition of NRG mediated activation of 3xNBox promoter activity in C2C12 cells was 
detectable upon concomitant treatment with TNF-α. In the next step, the function of 
GAbp on the natural AChRε promoter was elucidated. 
3.4.2 Neuregulin Promoted Induction of AChRε Promoter Activity is 
inhibited in the Presence of TNF-α 
In order to assess whether the TNF-α mediated dissociation of the heterodimeric GAbp 
complex plays a role in the expression of AChRε, an AChRε promoter assay was 
performed in C2C12 cells. For this purpose, an AChRε promoter driven luciferase 
plasmid was cloned. In this study, the promoter fragment ranging from 152 bp upstream 
of the transcription start site, which contains the N-Box, was used (Duclert et al. 1993).  
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Figure 33: Illustration of the murine AChRε promoter. This promoter sequence was cloned resulting 
in pGL3-AChRε plasmid and was subsequently used in AChRε promoter studies in C2C12 cells. Muscle-
specific transcription factors, from the MyoD protein family for instance, bind to the myogenic E-Box 
consensus motif (CAGCTG) thereby driving muscle-specific expression. Since this is a palindromic 
sequence two E-Boxes are indicated. The heterodimeric GAbp protein binds to the N-Box (CGGAA), an 
Ets-binding site. 
This promoter fragment has previously been shown to be sufficient for local restricted 
expression of AChRε in the sub-synaptic muscle cells. In addition, this sequence 
contains an E-Box crucial for muscle-specific gene expression (Figure 33). The 
promoter fragment (~ 300 bp) was amplified via PCR from murine genomic DNA by 
using the AChRe-Mm-promoter-for and AChRe-Mm-promoter-rev primer pair 
(2.4.2.1). Following this, the promoter fragment and the vector pGL3 were double 
digested with KpnI and NheI, ligated and the cloning procedure completed according to 
2.4.12.  
For corresponding promoter assays, an overexpression construct for GAbpβ was also 
required. The coding sequence of Gabpβ was amplified via PCR from a C2C12 cDNA 
pool by using primer Gabpβ-for and Gabpβ-rev, and subjected to restriction digest with 
NheI and XhoI along with the vector pcDNA3.1 (-) vector (2.4.2.1, 2.4.3). Upon 
completion of the cloning procedure, this overexpression plasmid for GAbpβ 
(pcDNA3.1(-)GAbpβ) was used in AChRε promoter assays. The cloning of the 
overexpression plasmid pcDNA3.1(-)GAbpα is described in 3.2.1. Next, the AChRε 
promoter fragment was tested in C2C12 cells. C2C12 myoblasts were transfected with 
pGL3-AChRε or the control plasmid (pGL3), CMV-ß-gal, pcDNA3.1(-)GAbpα, and 
pcDNA3.1(-)GAbpβ (2.1.7). Following this, cells were stimulated for 48 h with vehicle 
(PBS + 0.1% BSA) or 5 nM Neuregulin in the presence or absence of 25 ng/mL TNF-α 
(2.1.5). Finally, the relative luciferase activity was determined (Figure 34). 
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Figure 34: NRG mediated induction of the AChRε-promoter in C2C12 cells is inhibited by TNF-α. 
C2C12 cells were transfected with CMV-β-gal, pcDNA3.1(-)GAbpα, pcDNA3.1(-)GAbpβ and pGL3 or 
pGL3-AChRε and treated for 48 h with 5 nM NRG, 25 ng/mL TNF-α or both stimuli together. Thereafter, 
the relative luciferase activity was determined and normalized to NRG stimulation (N = 12, 4 independent 
experiments, mean ± SEM, * p < 0.001, two-way ANOVA with Bonferroni posttests comparing vehicle 
vs NRG in the absence or presence of the TNF-α). 
The AChRε promoter activity was significantly induced upon stimulation with NRG. 
This effect was even greater (80% increase) than NRG mediated induction of the 
3xNBox promoter (~ 45% increase). Also, treatment with TNF-α caused a slight 
increase in AChRε promoter activity when compared to untreated control. Yet, the 
presence of TNF-α caused a significant decrease in NRG-mediated induction of the 
promoter activity. Thereby, the interaction between NRG and TNF-α treatment was 
significant (Interaction p < 0.0001). The control promoter (pGL3) showed no altered 
transcriptional activity under these conditions, thus, supporting the notion that the effect 
observed here is specific to the AChRε promoter. Promoter analysis in C2C12 cells 
without concomitant overexpression of GAbp caused similar changes of promoter 
activity under these conditions (data not shown). However, since this was dependent on 
recruitment of endogenous GAbp, the extent of NRG-mediated induction and decrease 
by concomitant TNF-α treatment was lower. Based on this result, concomitant 
overexpression of GAbp was found to be more appropriate for promoter analysis. 
In order to investigate, whether this effect was mediated by binding of GAbp to the N-
Box, an N-Box mutant promoter was cloned by replacing the N-Box consensus motif 
through an EcoRI restriction site. This mutation strategy allowed for amplification of 
the upstream and downstream region of the N-Box by two PCR reactions and 
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subsequent ligation of correspondingly digested PCR fragments into the pGL3 vector. 
Therefore, two PCR primers were designed containing the mutated nucleotides in the 
middle and a complementary stretch of basepairs at the 5´- and 3´-ends. Following this, 
the sequence upstream and downstream of the mutated N-Box (N-Boxmut) was 
amplified by two different PCR reactions using the pGL3-AChRε plasmid as template 
(2.4.2.1). The N-Boxmut upstream region was amplified by combining the primer 
AChRe-Mm-prom-for with N-Boxmut-mAChRe-prom-rev for one PCR reaction, while 
the primer N-Boxmut-mAChRe-prom-for and AChRe-Mm-prom-rev were used for 
obtaining the N-Boxmut downstream region. The upstream PCR fragment was digested 
with KpnI and EcoRI, while EcoRI and NheI were taken for digestion of the 
downstream PCR fragment (2.4.3). Following this, these fragments were ligated to the 
accordingly with KpnI and NheI digested pGL3 vector (2.4.7). The cloning procedure 
was completed as described in 2.4.12.  
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Figure 35: The basal promoter activity of the AChRε-Nboxmut promoter C2C12 cells was 
extremely low. Cells were transfected with CMV-β-gal, pcDNA3.1(-)GAbpα, pcDNA3.1(-)GAbpβ and 
pGL3-AChRε or pGL3-AChRε-NBoxmut and treated for 48 h with 5 nM NRG, 25 ng/mL TNF-α, or both 
stimuli together. Thereafter, the relative luciferase activity was determined and normalized to NRG 
stimulation of the control vector (pGL3-AChRε) (N = 12, 4 independent experiments, mean ± SEM, * p < 
0.001, two-way ANOVA with Bonferroni posttests comparing vehicle vs NRG in the absence or presence 
of the TNF-α). 
The promoter plasmid pGL3-AChRε-NBoxmut was then tested in a promoter assay in 
C2C12 cells (2.1.7). As a control, the AChRε promoter plasmid containing the intact N-
Box was used (pGL3-AChRε). Deletion of the N-Box resulted in a significantly lower 
basal AChRε promoter activity compared to the promoter containing the intact N-Box 
(Figure 35). In addition, NRG mediated stimulation was much less pronounced. Based 
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on this relatively low basal as well as induced promoter activity, this experiment was 
found to be unsuitable for analyzing an implication of the NBox in TNF-α dependent 
decrease.  
3.4.3 Implication of Pro-Inflammatory Cytokines in Inhibition of NRG 
Mediated Induction of AChRε Promoter Activity and Gene Expression 
Next, the specificity of this TNF-α dependent decrease of AChRε promoter activity 
under pro-inflammatory conditions was addressed by comparison to other cytokines. 
AChRε promoter studies were performed as described before (2.1.7).  
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Figure 36: TNF-α, IL-1β and conditioned RAW medium (CM-RAW) inhibited NRG mediated 
activation of the AChRε promoter in C2C12 cells. Cells were transfected with CMV-β-gal, 
pcDNA3.1(-)GAbpα, pcDNA3.1(-)GAbpβ and pGL3-AChRε and stimulated for 48 h with vehicle or 5 
nM NRG plus 25 ng/mL TNF-α, 50 U/mL IFN-γ, 100 ng/mL LPS, 20 ng/mL IL-6, 10 ng/mL IL-1β (N = 
9, 3 independent experiments) or conditioned RAW medium (N = 6, 2 independent experiments). 
Relative luciferase activity was measured thereafter and normalized to NRG stimulated AChRε promoter 
activity (mean ± SEM, * p < 0.05, two-way ANOVA with Bonferroni posttests comparing vehicle vs 
NRG in the control setting or presence of a pro-inflammatory stimulus). 
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C2C12 cells were stimulated for 48 h with vehicle or 5 nM NRG and concomitantly 
treated with 25 ng/mL TNF-α, 50 U/mL IFN-γ, 100 ng/mL LPS, 20 ng/mL IL-6, or 10 
ng/mL IL-1β (Figure 36) (2.1.5). The basal (unstimulated) promoter activity was 
diminished slightly by IFN-γ, CM-RAW or IL-6, while it was not altered by TNF-α or 
IL-1β. Again, concomitant treatment with TNF-α and NRG caused a diminished AChRε 
promoter activity (70% decrease) as compared to NRG stimulation in the absence of 
TNF-α (Interaction p < 0.0001) (Figure 36). A similar effect was detected by 
concomitant treatment with IFN-γ (Interaction p < 0.0001) or IL-1β (Interaction p < 
0.0001), both cytokines causing a 70% decrease of AChRε promoter activity. Co-
treatment with conditioned RAW medium (Interaction p < 0.05), IL-6 (Interaction p < 
0.0001) or LPS (Interaction p = 0.0019) resulted in only 50 % decrease of AChRε 
promoter activity.  
The results suggest that the decrease of AChRε promoter activity is not specific to TNF-
α. However, the various pro-inflammatory cytokines tested here have a different impact 
on decreasing AChRε promoter activity. Usually, promoter activity assays by 
overexpression of a promoter fragment display only those events occurring on the 
selected promoter fragment. Moreover, the in vivo events are ideally analyzed by 
expression analysis of the corresponding gene. Therefore, the endogenous expression 
levels of AChRε were analyzed in C2C12 myotubes for diminished expression during 
NRG expression in the presence of various pro-inflammatory cytokines. C2C12 cells 
were seeded on individual wells of 6-well plates, differentiated into myotubes, and 
stimulated on day 3 for 16 h with two different concentrations per cytokine in the 
presence of 5 nM NRG or vehicle (2.1.5). In a parallel experiment, conditioned RAW 
medium was used as a stimulus. Following this, RNA was isolated (2.5.1), cDNA 
synthesis (2.4.9) performed and relative transcript levels of AChRε measured by qRT-
PCR (2.4.2.2). 
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Figure 37: NRG induction of relative AChRε mRNA levels in C2C12 myotubes was most 
dramatically inhibited in the presence of TNF-α or conditioned RAW medium (CM-RAW). C2C12 
cells were differentiated into myotubes and subsequently stimulated for 16 h as indicated. RNA was 
extracted, cDNA synthesized and relative mRNA levels of AChRε determined by qRT-PCR. Relative 
mRNA levels were normalized to unstimulated control setting (N = 6, three independent experiments, 
mean ± SEM, * p < 0.05, Two-way ANOVA with Bonferroni posttests comparing vehicle vs NRG in the 
control setting or presence of a pro-inflammatory stimulus). 
AChRε gene expression was on average induced ~ 4 fold by NRG treatment (Figure 
37). This induction was, however, less (~ 2 fold) in the presence of RAW control 
medium. Only treatment with CM-RAW resulted in a significant decrease of basal 
AChRε transcript levels (70% decrease). These levels were not altered by single-
treatment with TNF-α, LPS, IL-6, IL-1β, or IFN-γ. The interaction between NRG 
treatment and LPS (Interaction p = 0.6775), IL-6 (Interaction p = 0.1170), IFN-γ 
(Interaction p = 0.1188), or IL-1β (Interaction p = 0.1432) treatment were statistically 
not significant. Posttesting revealed that the greatest decrease of NRG mediated AChRε 
gene expression was 37%, 36% and 33% in the presence of 20 ng/mL IL-6, 10 ng/mL 
IL-1β, and 100 U/mL IFN-γ respectively. However, TNF-α (Interaction p < 0.0001) and 
conditioned RAW medium (Interaction p = 0.00301) had both a significant impact on 
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decreasing NRG mediated gene expression of AChRε. In these cases, the interaction 
between these treatments was also significant. Noteworthy, TNF-α did efficiently 
inhibit NRG mediated gene expression by 64% in the presence of the lowest 
concentration tested (5 ng/mL TNF-α). The highest concentration TNF-α (25 ng/mL 
TNF-α) caused a similar strong decrease (73%) like conditioned RAW medium (77% 
decrease) of relative mRNA levels. 
The results demonstrate that NRG mediated induction of endogenous AChRε gene 
expression was similarly strong inhibited by TNF-α alone or CM-RAW, while other 
pro-inflammatory cytokines did not have any significant impact in this study. 
Furthermore, CM-RAW caused already a significant decrease of basal AChRε gene 
expression. 
3.4.4 ROS are implicated in TNF-α Mediated Inhibition of NRG Dependent 
AChRε Gene Expression 
As shown before, TNF-α mediated dissociation of GAbpα and GAbpβ was caused by 
ROS. In order to investigate, whether ROS were similarly implicated in the regulation 
of AChRε gene expression under pro-inflammatory conditions, C2C12 myotubes were 
stimulated as described before in the presence of ROS inhibitors. These cells were then 
subjected to analysis of relative AChRε mRNA levels. 
C2C12 cells were differentiated to myotubes and stimulated for 18 h with 5 nM NRG, 
25 ng/mL TNF-α, or both stimuli together (2.1.5). In a parallel experiment, cells were 
also stimulated with 1 mM H2O2. This ROS inducing agent was also used in a co-
stimulation experiment with NRG. Concomitant with the co-stimulation conditions 
(TNF-α + NRG and H2O2 + NRG), cells were also treated with 150 µM MnTBAP or 5 
mM NAC. Thereafter, RNA was extracted (2.5.1), cDNA synthesis carried out (2.4.9), 
and relative AChRε mRNA levels detected by qRT-PCR (2.4.2.2).  
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Figure 38: Relative mRNA levels of AChRε in C2C12 myotubes as measured by qRT-PCR. C2C12 
cells were allowed to differentiate into myotubes and subsequently stimulated as indicated for 18 h with 5 
nM NRG, 25 ng/mL TNF-α, 1 mM H2O2, 150 µM MnTBAP or 5 mM NAC (N = 4, two independent 
experiments, mean ± SEM, one-way ANOVA with Bonferroni´s multiple comparison test). 
Again, NRG stimulation of C2C12 myotubes caused a ~ 3.5 fold increase in relative 
mRNA levels of AChRε. Gene expression of AChRε was not significantly altered by 
single treatment with TNF-α or H2O2. Repeatedly, NRG-mediated increase of AChRε 
mRNA levels was significantly decreased in the presence of TNF-α. Interestingly, H2O2 
did also inhibit NRG mediated AChRε gene expression, however, not significantly due 
to the relatively high standard error mean (Figure 38). Concomitant stimulation of NRG 
plus TNF-α with MnTBAP did significantly rescue (73% rescue) a decrease in relative 
AChRε mRNA levels. The inhibition of NRG induced AChRε expression by H2O2 was 
even rescued > 100% by both ROS inhibitors, MnTBAP and NAC. 
Taken together, inhibition of NRG mediated AChRε gene expression by TNF-α or H2O2 
in C2C12 cells is caused by intracellularly activated ROS. 
3.5 Expression of Sub-Synaptic Genes is Decreased in a 
Mouse Model for Cancer Cachexia 
The Colon26 mouse model has been employed by A. Vegiopoulos (DKFZ) as in vivo 
model for Cancer Cachexia (Tanaka et al. 1990; Tsuruo et al. 1983). All experiments 
were performed according to 2.9. Upon tumour injection, affected mice undergo 
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significant muscle loss. In this study, skeletal muscle tissue of these animals was 
investigated for alterations of sub-synaptic gene expression. RNA was extracted from 
gastrocnemius muscle (2.5.2), targeted to cDNA synthesis (2.4.9) and qRT-PCR 
analysis of sub-synaptic genes (2.4.2.2). While the expression of the ubiquitin ligase 
MuRF1 was significantly induced in Colon25 bearing mice, the expression of GAbp 
was slightly upregulated (Figure 39). In contrast, AChRe and AChR-Esterase 
(AChREst)-expression was significantly decreased, and the expression of AChR delta-
subunit (AChRδ), utrophin, and MuSk were slightly downregulated.  
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Figure 39: Expression analysis of sub-synaptic genes from gastrocnemius skeletal muscle tissue of 
Colon26 bearing tumor mice. Mice were treated and sacrificed as described in 2.9. Relative mRNA 
levels were normalized to GAPDH. (* p < 0.05, mean ± SEM). 
In brief, these findings suggest, that the expression of GAbp target genes is similarly 
regulated in this in vivo model for cancer cachexia as compared to C2C12 muscle cells 
exposure to atrophic stimulation. 
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4 Discussion 
 
This study presents the identification of GAbp as novel transcriptional regulator with 
dysregulated transcriptional activity under pro-inflammatory conditions in muscle cells. 
Furthermore, the dysregulated transcriptional activity is caused by dissociation of the 
DNA-binding component (GAbpα) and transcriptional activation component (GAbpβ) 
in the presence of TNF-α or conditioned macrophage medium. This pro-inflammatory 
signalling causes formation of reactive oxygen species and links GAbp dissociation to 
decreased gene expression of GAbp sub-synaptic target genes in muscle cells. 
4.1 A Screen Approach to Identify Novel Transcriptional 
Regulators with Dysregulated Activity in Response to Atrophic 
Stimulation 
In this study, a cell-based high-throughput screen was employed to find novel 
transcriptional regulators with dysregulated transcriptional activity in atrophic 
signalling. Previously, the transcription factor Foxo was discovered in muscle 
dysfunction accompanying muscle atrophy to up-regulate ubiquitin ligases, which target 
the degradation of muscle proteins (Sandri et al. 2004, Stitt et al. 2004). Thereby, the 
analysis of protein expression levels in different in vivo models for muscle atrophy 
paved the way for finding new targets in atrophic signalling (Bodine et al. 2001). 
Despite this work in elucidating the molecular mechanisms in muscle atrophy, it seems 
plausible that also other transcription factors are involved in the gene expression 
changes which accompany muscle dysfunction. Furthermore, the screen presented in 
this study, expands the search for novel targets to a more global and unconfined 
perspective by monitoring changes in protein activity of transcriptional regulators 
downstream of atrophic signalling pathways. 
The screen design entailed two major constrains. First, the library of transcriptional 
regulators consisted of fusion proteins each with an N-terminal Gal4 DNA binding 
domain. This may modify the protein folding process or even mask certain protein-
protein interaction domains. Second, due to the ease of transfection, the screen was 
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performed in HEK293T cells, a human mammalian cell line. Due to the low transfection 
efficiency of C2C12 cells, this cell line was not appropriate for this screen. The cellular 
environment of HEK293T cells provided the proteins from the basal transcriptional 
machinery being as well as co-regulators, which may by subjected to tissue-specific 
expression. Therefore, potential transcriptional interaction partners might be missing in 
HEK293T cells, and, thus, will not show up as hits in the screen. The fact, that 40% of 
the murine and 60% of the human factors showed an alteration of transcriptional 
activity, suggests that a human cell environment slightly favours functional interactions 
amongst proteins from the same species. Moreover, the changes of transcriptional 
activity were also greater for human factors compared to murine factors. 
More factors showed an altered transcriptional activity upon treatment with TNF-α 
(40%) than with Dex (26%). The canonical glucocorticoid pathway requires the 
presence of the glucocorticoid receptor (GR) and converges within the nucleus in 
transcriptional control of target genes. The fact that HEK293T cells lack the GR 
allowed for screening of transcriptional regulators, which are influenced in their activity 
by other glucocorticoid mediated signalling pathways (Beck et al. 2008). For instance, 
the family of Foxo transcription factors was previously discovered and implicated in 
glucocorticoid mediated muscle atrophy without a functional interactions with the GR 
(Accili & Arden 2004). In this study, novel transcription factors with altered activity in 
Dex treated cells were not found, probably because the majority of intracellular 
signalling pathways triggered by Dex required the presence of GR. 
TNF-α induces the transcriptional activity of NF-κB which in turn interacts with diverse 
proteins thereby influencing probably other pathways (Bouwmeester et al. 2004). In this 
study, TNF-α caused a change of transcriptional activity in more transcriptional 
regulators and induced also the greatest fold changes of transcriptional activity of 
individual transcriptional regulators as compared to the unstimulated setting. Overall, 
these fold changes were lower when compared to an alternative screen design, in which 
along with the Gal4 fusion proteins another protein was overexpressed (Amelio et al. 
2007). In the latter scenario, the functional interaction of the overexpressed protein with 
individual factors from the screen is focus of interest. In this context, GR co-
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transfection with individual Gal4 fusion proteins from the screen led to stronger fold 
changes of relative luciferase activity (data not shown). However, this screen design 
limits the interactions of individual Gal4 fusion protein to those occurring with the 
overexpressed protein of interest and is therefore not ideal when seeking for novel 
transcriptional regulators. In summary, the recruitment of endogenous proteins by 
Dexamethasone or TNF-α triggered signalling induces a relatively low change of 
transcriptional activity as compared to parallel overexpression of GR or NF-κB but 
broadens also the list of emerging targets. 
Retesting of putative TNF-α targets from the screen revealed that the alterations of 
relative luciferase activity for the majority of targets could not be reproduced. The 
reason for this may be either clonal variations in the cell line used for the screen and for 
retesting, or that some of the TNF-α targets were false positives. Among those tested, 
two targets, Gal4-GAbpα and Gal4-PSPC1, showed reproducible alterations of 
transcriptional activity in HEK293T cells. Upon validation of these targets in the murine 
muscle cell line C2C12, no transcriptional activity was detected for PSPC1. The human 
PSPC1 protein shares ~ 98.3% consensus positions with the murine PSPC1 protein. 
This should theoretically allow functional interaction of the human PSCP1 protein to 
murine proteins in C2C12 cell. However, while GAbpα is ubiquitously expressed, 
PSPC1 shows strong expression in testis and moderate expression in lung, spleen and 
ovary. Thus, PSPC1 might not play a crucial role in muscle tissue and hence lack 
transcriptional activity in muscle cells. Interestingly, the transcriptional activity of 
GAbpα was similarly altered in the human HEK293T and the murine C2C12 cell line, 
respectively. The human and murine GAbpα protein shares 97.8% consensus positions, 
thus allowing for functional interactions of proteins from different species. Therefore, 
this protein was identified as novel transcriptional regulator with dysregulated activity 
in TNF-α signalling.  
To date, the transcriptional activity of GAbpα in the context of pro-inflammatory 
signalling has not been investigated. As mentioned before, GAbpα is the DNA-binding 
component of the heterodimeric Gabp complex, which activates genes of the respiratory 
chain as well as sub-synaptic target genes (Rosmarin et al. 2004, Virbasius, 1993 #33, 
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Yang, 2007 #35, Xue, 2007 #34). Moreover, it seemed appealing to investigate, whether 
altered gene expression patterns of these target genes in muscle cells under pro-
inflammatory signalling contribute to the functional disturbances observed in muscle 
atrophy. While respiratory chain proteins are correlated with energy production through 
oxidation of sugar or fats, sub-synaptic target genes are crucial for the innervation of 
muscle cells by the nervous system. A malfunction of oxidative phosphorylation may 
cause an accumulation of ROS within the cell and thereby cause tissue damage (Giorgio 
et al. 2007). Likewise, denervation of muscle tissue is known to cause muscle atrophy 
(Bodine et al. 2001). 
4.2 The Transcriptional Active GAbp Heterodimer Dissociates 
under Pro-Inflammatory Conditions 
Regulation of transcriptional activity can be accomplished on the protein level, by 
protein activity, by functional interaction with other transcriptional regulators or 
proteins of the basal transcription machinery, or by binding to DNA. In fact, while the 
DNA binding of GAbpα, and the protein-protein binding between GAbpα and GAbpβ 
are specific, a multitude of other proteins of the transcription complex can bind in a 
tissue-specific manner to GAbp (Rosmarin et al. 2004). The Pointed and OST domain 
of GAbpα are both involved in such interactions (Kang et al. 2008). Also, the N-
terminal Ankyrin repeat domain of GAbpβ represents a classical protein-protein 
interaction domain. In addition, posttranslational modifications are likewise a plausible 
way to regulate the transcriptional activity of a transcriptional regulator. In this respect, 
two phosphorylation sites had previously been determined for GAbpα being targeted by 
Erk and Jnk MAP kinases in NRG stimulated muscle cells (Fromm & Burden 2001). 
Due to experimental design, the regulation of GAbp transcriptional activity by DNA-
binding could be ruled out, since DNA-binding in the mammalian one-hybrid assay and, 
hence, also under screen conditions occurred exclusively via the Gal4 DNA binding 
domain. Equally important for the analysis of the altered transcriptional activity of 
GAbpα was GAbpβ, since the transcriptional activation domain of the transcriptional 
active GAbp heterodimer resides on this protein component (Batchelor et al. 1998). 
Interestingly, the interaction of GAbpα and GAbpβ decreased significantly upon TNF-α 
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stimulation providing the first hint for the mechanism of TNF-α regulating the 
transcriptional activity of GAbp. In the past, the domain structure of both GAbpα and 
GAbpβ has been investigated in detail, thus, providing a useful orientation about 
defined folding domains of both proteins, which were targeted while preparing 
corresponding domain deletions (Kang et al. 2008). Deletion of the N-terminally located 
OST domain of GAbpα caused a decreased interaction of Gal4-GAbpα with Vp16-
GAbpβ protein as compared to the full length Gal4-GAbpα protein (Figure 40). This 
might be explained by other proteins potentially binding to this domain and, thereby, 
enhancing the binding to GAbpβ. In a recently published study, binding of the histone 
acetyltransferase CBP/p300 to this domain has been presented (Kang et al. 2008). It is 
tempting to speculate, whether this component of the basal transcriptional machinery 
binds in parallel to GAbpβ, thereby, stabilizing the transcriptional active GAbp 
heterodimer. A similar observation, decreased interaction, was detected upon further 
deletion of the pointed domain (PNT) and phosphorylation site T280 of Gal4-GAbpα. 
In addition, truncation of the leucine zipper domain (LeuZip) plus transcriptional 
activation domain (TAD) and phosphorylation sites (S170, T180) of the Vp16-GAbpβ 
protein caused likewise a decreased interaction compared to the full length Vp16-
GAbpβ protein. A complete loss of the interaction was detected upon deletion of the 
OST, PNT, and Ets domain together in the Gal4-GAbpα protein. As mentioned earlier, 
this finding is according to previous studies in which the C-terminus plus the Ets 
domain of GAbpα were shown to be required for GAbpβ binding (Chinenov et al. 
2000). Deletion of the Leucine Zipper domain (LeuZip) in the Vp16-GAbpβ protein 
increased the interaction to Gal4-GAbpα implying that the binding between both 
proteins is stronger when homodimerization of GAbpβ is inhibited. Potentially, the 
direct binding of GAbpα and GAbpβ might be weaker in the heterotetramer due to 
sterical hindrance. 
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Figure 40: Domain structure of Gal4-GAbpα and Vp16-GAbpβ (A) and alterations of interaction 
(PPI) detected for corresponding domain deletions via the mammalian two-hybrid assay as 
compared to the full length protein (B). 
TNF-α mediated reduction of the functional interaction occurred with all tested domain 
deletions of Gal4-GAbpα as well as Vp16-GAbpβ, thus, suggesting that the minimal 
binding domains are also sufficient for TNF-α mediated dissociation. In addition, 
phosphorylation was not implicated in this dissociation. This is also in accordance with 
two recent studies, in which the phosphorylation of GAbpα and GAbpβ were both 
shown to be dispensable for NRG mediated transcription of AChR (Sunesen et al. 2003, 
Herndon, 2008 #46).  
Importantly, the dissociation of GAbpβ and GAbpα was specific to TNF-α, since other 
pro-inflammatory cytokines like IFN-γ, IL-6, IL-1β did not decrease the interaction 
between the minimal binding domains of Vp16-Gabpβ (dPhoSit) and Gal4-GAbpα 
(dT280). Only conditioned RAW medium decreased this functional interaction to a 
similar extent as TNF-α alone, thus suggesting that TNF-α release from conditioned 
macrophages is the specific stimulus for dissociation of the transcriptional active GAbp 
protein. In summary, the dissociation of GAbpβ and GAbpα represents a novel finding 
of regulating the transcriptional activity of GAbp under pro-inflammatory conditions in 
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muscle cells. In addition, the finding that the GAbp complex dissociates upon oxidative 
stress has not been addressed muscle cells so far. In previous studies the DNA binding 
activity of GAbp was inhibited by pro-oxidant conditions in 3T3 cells (Martin et al. 
1996). In addition, modification of Cys421 in GAbpα was identified to inhibit 
dimerization with GAbpβ in vitro; however, GAbp dissociation has not been addressed 
by in vivo techniques (Chinenov et al. 1998). Therefore, this is the first report of redox 
regulated GAbp activity in muscle cells. This finding is of major interest, since ROS 
have been suggested to mediate the intracellular signalling pathways of TNF-α and 
modulate many inflammation-induced alterations of muscle function (Garg & Aggarwal 
2002, Supinski, 2007 #68). In addition, ROS are implicated in skeletal muscle insulin 
resistance, which is in turn accompanied by oxidative stress and low-grade 
inflammation (Wei et al. 2008). Consequently, the identification of GAbp dissociation 
under pro-inflammatory conditions in muscle cells involving the action of ROS may 
provide a novel link between inflammatory mediators and the subsequent alteration in 
muscle specific gene expression. 
4.3 Expression of Sub-synaptic Genes is altered Under Pro-
Inflammatory Conditions 
Ets transcription factors are downstream targets of signalling pathways and can interact 
with a multitude of proteins of the transcription complex in a cell-type specific manner 
(Sharrocks 2001). This characteristic is highlighted by ubiquitous expression of GAbp; 
however, liver, muscle and hematopoietic cells represent the major tissue sites for 
GAbp (Rosmarin et al. 2004). In muscle tissue, GAbp organizes the neuromuscular 
junction (NMJ) by activating transcription of sub-synaptic genes in the innervated 
muscle cell (Briguet & Ruegg 2000). The presence of the NBox, a consensus-motif for 
binding of GAbp, in the promoter sequences of these genes drives the 
compartmentalized transcription of AChRε for instance. Consequently, it was of 
specific interest to analyze whether GAbp dissociation under pro-inflammatory 
conditions finally results in a reduced expression of sub-synaptic target genes in muscle 
cells. 
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Analysis of an artificial 3xNBox promoter in C2C12 cells confirmed the previously 
described NRG mediated induction of NBox containing promoter activity (Lee et al. 
2004). Since GAbp was identified as the protein binding component of the NBox, it is 
plausible that induction of NBox containing promoter activity occurs through 
recruitment of endogenous GAbp to the NBox consensus motif (Schaeffer et al. 1998).  
Stimulation with TNF-α alone did not alter the promoter activity, probably because 
under basal conditions the endogenous complex is not bound to DNA and hence a 
dissociation of the complex in solution does not have an impact on gene expression. As 
alternative explanation, the endogenous GAbp complex might be stabilized by other 
proteins of the basal transcription complex in TNF-α treated cells. Under the same 
conditions, the access of these proteins in the mammalian two-hybrid assay might be 
sterically hindered due to the Gal4 and Vp16 tags. Interestingly, NRG treatment in the 
context of the mammalian two-hybrid assay did not increase the interaction between 
GAbpα and GAbpβ (data not shown), which is in accordance with a previous study 
proposing that both subunits form a stable heterodimer in solution (Chinenov et al. 
2000). However, NRG stimulation in the presence of TNF-α did significantly restrict 
3xNBox-promoter activity, even though the significance test for interaction between 
both parameters (NRG and TNF-α stimulation) was not significant (Interaction P = 
0.0863) probably due to low sample number. In this scenario, NRG drives probably the 
recruitment of the GAbp complex to NBox consensus motif while TNF-α counteracts 
this transcriptional activation process by causing a dissociation of both proteins. 
This finding is highlighted by promoter assays in C2C12 cells using the natural AChRε 
promoter, where TNF-α efficiently restricts NRG mediated increase of AChRε promoter 
activity. In this case, the NRG-mediated induction of promoter activity was even more 
pronounced, thus, suggesting, that further regulatory motifs in the promoter sequence 
and/or further transcriptional regulators and proteins of the basal transcription 
machinery modulate promoter activity. Surprisingly, TNF-α treatment alone caused an 
upregulation of AChRε promoter activity. As mentioned before, this can be explained 
by the fact, that a 300 bp AChRε promoter fragment contains even more regulatory 
sequences (for example the E-Box), which contribute to AChRε promoter activity, than 
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the artificial 3xNBox promoter. Alternatively, NRG-mediated AChRε-expression has 
been previously correlated with activation of the c-JUN N-terminal kinase (JNK) (Si et 
al. 1999). Since TNF-α can likewise activate JNK, this may explain the relatively mild 
activation of AChRε-promoter activity by TNF-α treatment (Kamata et al. 2005). 
Thereafter, the specificity of this finding was addressed by comparison with other pro-
inflammatory cytokines. While IFN-γ and IL-1β did significantly inhibit NRG induced 
AChRε-promoter activity, the corresponding AChRε mRNA levels were not 
dramatically altered in C2C12 myotubes. Analysis of LPS and IL-6 led so similar 
results. Moreover, the interaction between cytokine and NRG was significant for all 
cytokines tested in the AChRε promoter studies, but failed to obtain significance status 
in the corresponding qRT-PCR analysis. In the latter, the interaction was only 
significant for TNF-α and CM-RAW. Thus, IFN-γ, IL-1β, LPS, and IL-6 have less 
impact on inhibiting NRG mediated increase of AChRε mRNA levels. TNF-α treatment 
alone did not alter AChRε mRNA levels but blocked efficiently NRG mediated increase 
in AChRε mRNA levels. Interestingly, CM-RAW did not only inhibit NRG mediated 
increase of AChRε mRNA levels to a similar extent like TNF-α, but decreased the very 
same also in the absence of NRG. In short, CM-RAW and TNF-α do efficiently block 
NRG mediated increase of AChRε gene expression. This is in accordance with the 
above described finding from the mammalian two-hybrid assay, where TNF-α 
stimulation alone likewise contributed significantly to GAbp dissociation as the 
treatment with CM-RAW. Most importantly, oxidative stress decreased also AChRε 
mRNA levels in C2C12 myotubes. Despite the fact, that this change was not significant 
due to a relatively high standard error mean, the trend is a novel finding. Concomitant 
treatment with ROS inhibitors dramatically rescued this inhibition as well as the TNF-α 
mediated decrease of AChRε mRNA levels, thus linking pro-inflammatory conditions 
to decreased gene expression of sub-synaptic GAbp target genes by activation of ROS. 
Interestingly, the activity of an artificial GAbp responsive promoter was decreased in 
3T3 cells upon depletion of the ROS-scavenging peptide glutathione supporting the 
finding presented in this study in muscle cells (Martin et al. 1996). Strikingly, 
expression levels of mitochondrial GAbp target genes, which function in the oxidative 
phosphorylation (i.e. ATP synthase, cytochrome oxidase subunits IV and Vb), were not 
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altered under these settings (data not shown) suggesting that the transcriptional activity 
of GAbp is subjected to context- and tissue-specific regulation.  
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Figure 41: Proposed model of regulation of transcriptional activity of GAbp by ROS in muscle cells 
under pro-inflammatory conditions. NRG stimulation causes binding of GAbp to NBox consensus 
motifs within promoter sequences of sub-synaptic target genes and increases thereby the transcription of 
the these genes. This expression is significantly decreased in muscle cells during pro-inflammatory 
stimulation through activation of ROS and concomitant dissociation of GAbp. 
To summarize, this study gives rise to following molecular model for linking pro-
inflammatory conditions to novel altered gene expression pathways in muscle cells. 
Stimulation of muscle cells with TNF-α decreases expression of GAbp sub-synaptic 
target genes by activation of ROS, and dissociation of the transcriptional active GAbp 
heterodimer (Figure 41). As mentioned before, the activity of Foxo proteins is regulated 
by phosphorylation thereby targeting the up-regulation of ubiquitin ligases in different 
models of muscle atrophy (Sandri et al. 2004; Stitt et al. 2004). The redox regulation of 
the Ets transcription factor GAbp and concomitant altered expression of sub-synaptic 
target genes will contribute to the elucidation of the molecular mechanisms in atrophic 
signalling. Thereby, this study extends the previous discovery of muscle proteins being 
targeted in muscle atrophy (i.e. myosin, MyoD) to those proteins crucial for the proper 
innervation of muscle tissue, a yet unknown link. 
So far, no study has addressed the NRG mediated formation of the transcriptional active 
heterodimer or heterotetramer on NBox containing DNA sequences in vivo. Preliminary 
chromatin immunoprecipitation experiments in C2C12 myotubes, which have been 
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performed in this study (data not shown) to investigate the dissociation of GAbp on the 
AChRε promoter in C2C12 myotubes under pro-inflammatory conditions, suggest a 
link of GAbp dissociation to AChRε gene expression. However, due to the low 
abundance of GAbpα and GAbpβ in muscle cells, enrichment of GAbpβ binding upon 
NRG treatment was very low (~ 1.5-fold). Despite this fact, less GAbpβ binding was 
detectable by co-stimulation with NRG plus TNF-α treatment, thus providing a link 
between GAbp dissociation and altered AChRε gene expression. In addition, a direct 
evidence for the implication of GAbp dissociation in reduction of AChRε gene 
expression in muscle cells under pro-inflammatory conditions can be investigated by 
overexpression of TNF-α resistant GAbp in muscle cells. In this context, the presence of 
redox sensitive Cys-residues within the N-terminal binding domain of GAbpα suggests 
that these residues maybe targeted by ROS (Chinenov et al. 1998). 
In the past, NF-κB and activator protein (AP)-1 have already been identified as redox 
regulated transcription factors (Sen & Packer 1996). While redox sensitive Cys residues 
of GAbpα are implicated in heterodimerization with GAbpβ, this redox regulation has 
never been investigated in muscle cells. A decreased expression of sub-synaptic target 
genes in muscle cells, which is described in this study, suggests that inflammatory 
conditions may cause denervation of muscle cells through induction of ROS species and 
subsequent dissociation of the transcriptional active GAbp heterodimer. Unbalanced 
ROS levels cause damage to cells by oxidation of DNA, protein and membrane damage. 
In this context, ROS are probably implicated in Duchenne muscular dystrophy (DMD), 
a degenerative neuromuscular disease (Whitehead et al. 2006). Interestingly, transcript 
levels of AChRε were found to be significantly decreased in the skeletal tissue from of 
Colon26 mice, a model for cancer cachexia, thus, supporting the finding presented in 
this study from cell culture experiments. Finally, it is tempting to speculate, that muscle 
wasting, which is also observed in elderly people, arises from accumulation of ROS 
during ageing and concomitant denervation by above mentioned molecular pathway. 
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6 Materials 
 
6.1 Instruments 
 
Product Distributor 
Centrifuge (Super T 21) Sorvall 
Centrifuge (Minifuge, RF) Heraeus 
Centrifuge (Mikro 22R) Hettich GmbH & Co KG 
Centrifuge (Labofuge 400R) Heraeus 
Centrifuge (Biofuge pico) Heraeus 
Centrifuge (Biofuge fresco) Heraeus 
CO2 Incubators SANYO 
Elektrophoresis Power Supply, Power Pac HC/Basic Bio-Rad 
Gel Doc Apparatus Bio-Rad 
Gene Pulser II Bio-Rad 
iCycler Thermal Cycler Bio-Rad 
SDS Gel Apparatus Bio-Rad 
Table Centrifuge (miniSpin plus) Neolab 
Thermomixed comfort Eppendorf 
Real time PCR System 7300 Applied Biosystems 
SW28 Ti rotor Beckman  
TissueLyser QIAGEN 
NanoDrop, ND-1000 Spectrophotometer Peqlab 
Microscope, Axiovert 40 CFL  Carl Zeiss 
Multidrop 384 Thermo Scientific 
Luminometer microplate Mithras LB 940 Berthold technologies 
Sonifier W-250 Branson 
1430 ultra(HTS) microplate Imager ViewLux System PerkinElmer 
Ultracentrifuge XL-70 Beckman 
Ultrospec 3000pro UV/Visible Spectrophotomoeter GE Healthcare Life 
Sciences 
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6.2 Consumables 
 
Product Distributor 
Tissue Culture Plates (12-well plates) Nunc 
Tissue Culture Plates (10 cm, 15 cm, 6-well) Falcon 
96-well plates (black, transparent) Nunc 
6.3 Chemicals & Cytokines  
All routinely used chemicals were purchased from Roth. 
Product Distributor 
Agrin, recombinant rat C-terminal R&D Systems 
Albumin, Bovine Fraction V solution (30%), sterile filtered Sigma 
Ampicillin Sigma 
Bio-Rad Protein Assay (Bradford Reagent) Bio-Rad 
BrightLite PerkinElmer 
Bovine Serum Albumine (BSA), 10 mg/ mL NEB 
Centrifuge tubes, Polyallomer quickseal Beckman Coulter 
Chloramphenicol Sigma 
Calf Intestine Phosphatase (CIP) NEB 
Crystal Violet Solution Sigma 
Dexamethasone Sigma 
DMEM, 4500 mg/L D-Glucose, with Glutamine Invitrogen 
DNase/RNase free Water Invitrogen 
DNase set QIAGEN 
Fetal Calf Serum (FCS) Invitrogen 
Gene RulerTM 1kb DNA Ladder  Fermentas 
Geneticin Invitrogen 
HyperfilmTM ECL GE Healthcare, 
Amersham 
HyperfilmTM ECL Western Blotting Detection Reagents GE Healthcare, 
Amersham 
IgG-HRP (anti-mouse, anti-rabbit) Bio-Rad 
Interferon-γ, recombinant, mouse (mIFN- γ) Roche Diagnostics 
Interleukin 1 beta, recombinant, mouse USBiological 
Interleukin 6, recombinant, mouse USBiological 
T4 DNA-Ligase (400 kU/ mL) NEB 
MATERIALS 
 
 
107 
Kanamycin Sigma 
L-Glutamine Invitrogen 
LipofectamineTM Reagent Invitrogen 
Lipopolysaccharides E.coli  Sigma 
Luciferin Sigma 
Mass RulerTM Low range DNA Ladder Fermentas 
MEM Non-Essential Amino Acids Invitrogen 
Neuregulin, human NRG-β1/HRG-β1 EGF domain R&D Systems 
Nitrocellulose Membrane (0,45 µm) Schleicher und Schuell 
o-Nitrophenyl-β-D-galactopyranosid (ONPG) Sigma 
Nonidet NP40  (equivalent to Igepal) Sigma 
NZY Medium Roth 
Opti-MEM I Invitrogen 
Orange G Sigma 
Page RulerTM Unstained Protein Ladder Fermentas 
Penicillin/Streptomycin (P/S) Invitrogen 
Pepstatin Sigma 
PhusionTM High-Fidelity DNA Polymerase (2 U/ mL) Finnzymes 
Platinum® Quantitative PCR SuperMix Invitrogen 
PMSF  Sigma 
Polybrene (Hexadimethrine Bromide) Sigma 
Protein A/G PLUS-Agarose SCBT 
Protein A Agarose/ Salmon Sperm DNA Upstate 
QIAshredder Column QIAGEN 
QIAZOL QIAGEN 
Restriction Enzymes NEB 
RNaseZAP®  Sigma 
Sodium Pyruvate (100 mM), sterile filtered Sigma 
Tissue Culture dishes/plates Falcon 
TNF-α, human recombinant Alexis Biochemicals 
TNF-α, murine recombinant Biomol 
Trypsine-EDTA (0.25%) Invitrogen 
ZeocinTM Invitrogen 
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6.4 Kits 
 
Product Vendor 
2-D Quant Kit Amersham 
Block-iT™ Lentiviral Pol II miR RNAi Expression System Invitrogen 
Block-iT™ Pol II miR RNAi Expression Vector Kits Invitrogen 
First Strand cDNA Synthesis Kit Fermentas 
Gene Eraser™ Luciferase Suppression-Test System Stratagene 
PureLink7™ HiPure Plasmid FP Maxiprep Kit Invitrogen 
Qiaprep Plasmid Miniprep Kit QIAGEN 
QIAquick PCR Purification Kit QIAGEN 
Qiaquick Gel Extraction Kit QIAGEN 
RNeasy Mini Kit QIAGEN 
6.5 Bacterial Cells  
 
E.coli Source/Origin 
XL1-blue Stratagene 
OneShot Stbl3 Invitrogen 
OneShot TOP10 Invitrogen 
XL10-Gold Stratagene 
6.6 Mammalian Cell Lines 
 
Cell Lines Source/Origin 
C2C12 LP L. Puri, Burnham Institute 
C2C12 S Sigma 
RAW 264.6 R. Zawatzky, DKFZ 
HEK293FT Invitrogen 
HEK293T S. Herzig, DKFZ 
HEK293 S. Herzig, DKFZ 
6.7 Antibodies 
 
Antibody Final Dilution Species Company Cat. No # 
Gabpa (G-1) 1:200 – 1:1000 Mouse monoclonal SCBT Sc-28312 
Gabpa (H-180)  Rabbit polyclonal SCBT Sc-22810 
GAbpb2 (A01) 1:200 – 1:1000 Mouse polyclonal Abnova H00002553-
A01 
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GAL4 (DBD) 1:500 Rabbit polyclonal SCBT Sc-577 
GAL4, DNA binding 
domain mouse mAB 
(8C-1) 
1:2000 Mouse monoclonal Calbiochem 345766 
Myosin skeletal (fast) 
clone MY-32 
1:5000 Mouse monoclonal Sigma M 4276 
VCP  1:10000 Mouse monoclona abcam Ab11433 
6.8 Oligodesoxyribonucleotides  
 
6.8.1 Oligodesoxyribonucleotides for plasmid cloning 
 
Primer 
Name 
Oligonucleotide 
 
Resulting 
Plasmid 
Gabpα pos447 
for 
TTTTTGCGGCCGCATGACTAAGAGAGAAGCAGAAGAG 
Gabpα pos2401 
rev 
TTTTTGCGGCCGCAATAGTGGTTTGAGTTAAGCCAGC 
pTarget-
Gabpα-ORF 
Gabpα pos2443 
for 
TTTTTGCGGCCGCTTATTCATTATGTCAAGCCAAGGTC 
Gabpα pos4767 
rev 
TTTTTGCGGCCGCTCCCTTCTACAAAAGACTCAAGAG 
pTarget-
Gabpα-
3’UTR 
AChRe Mm 
promoter for 
TTTTTGGTACCGCCTTGTGGATTACAGAACTGGCTGAA
ACC 
AChRe Mm 
promoter rev 
TTTTTGCTAGCCTGACCCCTGTACCCTACCAAAGAGTG
TCAGG 
 
pGL3-
AChRe 
N-Box mut 
mAChRe prom 
for 
CAGTCCCCAAACCTAGCGGATCCCTAACACCC 
N-Box mut 
mAChRe prom 
rev 
GAAGGGGAGGAGGGTGTTAGGGATCCGCTAGGTTTG 
pGL3-
AChRe-
NBoxmut 
GAbpβ for TTTTTGCTAGCGTAATGTCCCTGGTAGATTTGGGGAAG 
GAbpβ rev TTTTTCTCGAGCTAAACGGCTTCTTTGTTGGTCTGG 
pcDNA3.1 
(-)Gabpβ 
GAbpβ Vp16 for TTTTTGGTACCTCCCTGGTAGATTTGGGGAAGAAG 
GAbpβ Vp16 rev TTTTTGCTAGCCTAAACGGCTTCTTTGTTGGTCTG 
Vp16-
Gabpβ 
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GAbpβ dLeuZip 
rev 
TTTTTGCTAGCCTCCGGGTTGGTGTTGATTTGGTTC dLeuZip 
GAbpβ dTAD 
rev 
TTTTTGCTAGCTTCAATTTCTGCACATTCCACCCG dTAD 
GAbpβ dPhoSit 
rev 
TTTTTGCTAGCCTGACCCCCTGAGCTAACTACTTGCTG dPhoSit 
Gabpa AscI rev TTTTTGGCGCGCCAATCTCTTTGTCTGCCTGTAGAGAG Gal4-Gabpα 
deletions 
dOST for PacI 
Gal4-Gabpa 
TTTTTTTAATTAACTGGGCTGCTGCACTGGAAGGCTAC dOST 
dPNT for PacI 
Gal4-Gabpα 
TTTTTTTAATTAACATTCCAGCCTCAGTGCCTCCCGC dPNT 
dT280 for PacI 
Gal4-Gabpα 
TTTTTTTAATTAACAACAATGGTCAGATCCAACTATGG dT280 
dEts for PacI 
Gal4-Gabpα 
TTTTTTTAATTAACCGGATGCAGCTGCATGGGATTGCC dEst 
6.8.2 Oligodesoxyribonucleotides for sequencing of plasmids 
 
Oligonucleotide Sequenced Plasmid 
CAGCTCTTAAGGCTAGAGTA pGAL4 for 
TGCTCGAAGCATTAACCCTC pGAL4 rev 
CTAGCAAAATAGGCTGTCCC pGL3 for 
CTTTATGTTTTTGGCGTCTTCC pGL3 rev 
GGCCGACTTCGAGTTTGAGC pVp16 for 
CATTGACGTCAATGGGAG pcDNA3.1(-) for 
6.8.3 Oligodesoxyribonucleotides for miRNA cloning 
 
Oligonucleotide miRNA ID 
CCTGTAAAGGTTAGAAAAGCTTGGTCAGTCAGTGGCCAAAACCAAGCTT
TGCTCTAACCTTTAC 
1256 bottom 
TGCTGTAAAGGTTAGAGCAAAGCTTGGTTTTGGCCACTGACTGACCAAG
CTTTTCTAACCTTTA 
1256 top 
CCTGACTACAGGCTATCAGACCTGTCAGTCAGTGGCCAAAACAGGTCTG
AGCTAGCCTGTAGTC 
4216 bottom 
TGCTGACTACAGGCTAGCTCAGACCTGTTTTGGCCACTGACTGACAGGTC
TGATAGCCTGTAGT 
4216 top 
CCTGAAGACATTAAGAGTCACAGGTCAGTCAGTGGCCAAAACCTGTGAC 4682 bottom 
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TGACTTAATGTCTTC 
TGCTGAAGACATTAAGTCAGTCACAGGTTTTGGCCACTGACTGACCTGTG
ACTCTTAATGTCTT 
4682 top 
6.8.4 Plasmids 
 
Plasmid DNA Source/Origin 
pCMV ßGal A. Vegiopoulos, DKFZ 
pGAL4 DBD M.D. Conkright, Scripps  
pGAL4 Luc M.D. Conkright, Scripps  
pGAL4 p65 Lienhard Schmitz, University of Bern 
pGAL4 GR S. Stoney Simsons, NIDDK 
pGAL4 GAbpa M.D. Conkright, Scripps 
pGAL4 Gabpa dOST A.M. Gail, DKFZ 
pGAL4 Gabpa dPNT A.M. Gail, DKFZ 
pGAL4 Gabpa T280 A.M. Gail, DKFZ 
pGAL4 Gabpa Ets A.M. Gail, DKFZ 
pGL3 Promega 
pGL3 AChRe A.M. Gail, DKFZ 
pGL3 AChRe Nbox mut A.M. Gail, DKFZ 
pcDNA3.1(-) Invitrogen 
pcDNA3.1(-)GAbpa A.M. Gail, DKFZ 
pcDNA3.1(-)Gabpb1 A.M. Gail, DKFZ 
pCMX Vp16 S. Herzig, DKFZ 
pVp16 Gabpb A.M. Gail, DKFZ 
pVp16 Gabpb dLeuZip A.M. Gail, DKFZ 
pVp16 Gabpb dTAD A.M. Gail, DKFZ 
pVp16 Gabpb dPhoSit A.M. Gail, DKFZ 
pTarget MCS Stratagene 
pTarget Gabpa ORF A.M. Gail, DKFZ 
pTarget Gabpa 3’UTR A.M. Gail, DKFZ 
pcDNA6.2 Invitrogen 
pcDNA6.2 miRNA 1256 A.M. Gail, DKFZ 
pcDNA6.2 miRNA 4216 A.M. Gail, DKFZ 
pcDNA6.2 miRNA 4682 A.M. Gail, DKFZ 
pcDNA6.2 miRNA NC A.M. Gail, DKFZ 
pLenti Invitrogen 
pLenti miRNA GAbpa A.M. Gail, DKFZ 
pLenti miRNA NC A.M. Gail, DKFZ 
MATERIALS 
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pMDL g/p RRE G. Schütz, DKFZ 
pMD2.G G. Schütz, DKFZ 
pRSVrev G. Schütz, DKFZ 
6.8.5 Taqman Probes 
 
Gene Name/Symbol ID 
AchRd, Chrnd Mm00445545_m1 
AchRe, Chrne Mm00437411_m1 
ErbB2 Mm00648541_m1 
GAbpa Mm00484598_m1 
Gabpb1 Mm00487471_m1 
GAPDH Mm99999915_g1 
Musk Mm00448006_m1 
TBP Mm00446973_m1 
Utrophin Mm01168858_m1 
6.9 Media 
 
Differentiation Medium for C2C12 cells DMEM  
+ 2% FCS 
+ 1% Penicillin-Streptomycin 
 
Freezing Medium for tissue culture DMEM 
+ 10% DMSO 
+ 20% FCS 
 
Growth Medium for C2C12 cells DMEM  
+ 20% FCS 
+ 1% Penicillin-Streptomycin 
 
Growth Medium for HEK293 and HEK293T cells DMEM 
+ 10% FCS 
+ 1% Penicillin-Streptomycin 
 
Growth Medium for HEK293FT cells DMEM 
+ 10% FCS 
+ 1% Penicillin-Streptomycin 
+ 500µg/mL Geneticin 
+ 0.1 mM MEM Non-Essential Amino 
Acids 
+ 1 mM Sodium Pyruvate 
+ 6 mM L-glutamine 
 
6.10 Recipes  
(if not otherwise indicated, the buffers, media etc. were prepared in the solvent water) 
 
Assay Buffer 15 mM K3PO4 
MATERIALS 
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1 mM DTT 
2 mM ATP 
in Gly-Gly Working Solution pH 7.8 
 
2x BBS 50 mM BES 
280 mM NaCl 
1.5 mM Na2HPO4 
pH 6.95 with NaOH 
 
Blocking Buffer PBST 
+ 5% non-fat dry milk  
 
Bromophenolblue (BPB) stock solution 150 mg BPB 
90 mg Tris 
 
Ethidium bromide stock solution  
 
10 mg/mL  
Gly-Gly Working Solution pH 7.8 25 mM Gly-Gly 
15 mM MgSO4 
4 mM EGTA 
 
IP-Buffer (Hardy) 20 mM HEPES/KOH pH 7.4 
125 mM NaCl 
0.1% Igepal 
0.5 mM EDTA 
1x PIC 
 
IP-Buffer (Larry) 20 mM HEPES/KOH pH 7.5 
150 mM NaCl 
1% Triton X-100 
1mM EGTA 
1.5 mM MgCl2 
10% Glycerol 
+ 1x PIC 
+ 50 mM NaF 
+ 1 mM Na3VO4 
 
Harvest Buffer for  
Luciferase- and ßGalactosidase-Assay 
Gly-Gly Working Solution pH 7.8 
+ 1% Triton X-100 
+ 1 mM DTT 
 
LB medium 10 g/L Trypton 
5 g/L Yeast Extract 
10 g/L NaCl 
pH 7.0 
 
Low salt LB medium 10 g/L Trypton 
5 g/L Yeast Extract 
5 g/L NaCl 
pH 7.5 
 
Luciferase-Buffer Gly-Gly Working Solution pH7.8 
+ 11.1% (v/v) Luciferase-Mix 
 
Luciferase-Mix 1 mM Luciferin 
10 mM DTT 
 
Lysis Buffer for genomic DNA extraction 10 mM Tris pH 8.0 
MATERIALS 
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100 mM NaCl 
15 mM EDTA 
0.5% SDS 
0.5mg/mL Proteinase K 
 
10x MOPS buffer 200 mM MOPS 
50 mM NaAc 
10 mM EDTA 
pH 7 
ad 1 L RNase free water 
 
ONPG Buffer 0.1 M Sodium phosphate pH 7.5 
1 mM MgCl2 
10 mM KCl 
1 mg/mL ONPG 
 
6x Orange G DNA loading buffer 10 mM EDTA 
70% Glycerol 
a pinch Orange G  
 
1x PBS 140 mM NaCl 
1.5 mM KH2PO4 
11.3 mM Na2HPO4 
2.7 mM KCl 
 
1x PBST PBS 
0.1% Tween 20 
 
50x Protease Inhibitor Cocktail (PIC) 
 
50 mM PMSF 
50 mM NaF 
0.5 mg/mL Leupeptin 
0.5 mg/mL Aprotinin 
0.5 mg/mL Pepstatin 
in ethanol 
 
RNA Denaturing Buffer 
(indicated volumes refer to one RNA sample) 
0.5 mg/mL ethidium bromide 
0.5x MOPS buffer 
66.6% formamide 
8.9% formaldehyde 
1x loading dye 
ad 10 µL RNase free water 
 
SDS Running Buffer 25 mM Tris 
190 mM Glycine 
1% SDS 
0.45% HCl 
 
2x SDS Reducing buffer 120 mM Tris/HCl pH6.8 
4% (w/v) SDS 
20% Glycerol 
200 mM DTT 
0.01% BPB (1mg/mL) 
 
 2x SDS sample buffer + 8 M Urea 8 M Urea  
200 mM DTT 
120 mM Tris 
4% SDS 
20% Glycerol 
MATERIALS 
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0.01% Bromphenolblue 
 
Sodium Phosphate (0.1 M pH 7.5) 41 mL of 0.2 M Na2HPO4*2H2O 
9 mL 0f 0.2 M NaH2PO4*2 H2O 
ad 100 mL H2O 
 
1x TBE Buffer 45 mM Tris 
44 mM Boric Acid 
1 mM EDTA 
 
1x TE Buffer 10 mM Tris  
1 mM EDTA 
 
1x Transfer Buffer 25 mM Tris 
192 mM Glycine 
0.01% SDS 
20% Methanol 
 
 
 
 
